

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number
WO 02/04684 A1

(51) International Patent Classification⁷: **C12Q 1/68**, (74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(21) International Application Number: **PCT/US01/21999**

(22) International Filing Date: 12 July 2001 (12.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/217,773 12 July 2000 (12.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US Not furnished (CIP)
Filed on Not furnished

(71) Applicant (for all designated States except US): **THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK** [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MORSE, Jane, H.** [US/US]; 4662 Iselin Avenue, Bronx, NY 10471 (US). **KNOWLES, James, A.** [US/US]; 22 Thomas Street, Rowaytn, CT 06853 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1
WO 02/04684

(54) Title: **ROLE OF PPH1 GENE IN PULMONARY HYPERTENSION**

(57) Abstract: This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises: 1) obtaining a suitable sample from the subject; 2) detecting in the sample a bone morphogenetic protein receptor-II mutation which is not present in wildtype bone morphogenetic protein receptor-II, wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease. In one embodiment, the pulmonary disease is Familial Primary Pulmonary Hypertension.

ROLE OF PPH1 GENE IN PULMONARY HYPERTENSION

- 5 This application is a continuation-in-part and claims the benefit of U.S. Provisional Application No. 60/217,773, filed July 12, 2000, the contents of which are hereby incorporated by reference into this application.
- 10 The invention disclosed herein was made with Government support under NIH Grant No. HL60056-02 from the National Heart, Lung and Blood Institute. Accordingly, the government has certain rights in this invention.
- 15 Throughout this application, various publications are referenced within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full
20 bibliographic citations for these references may be found immediately preceding the claims.

Background of the Invention

25

Familial Primary Pulmonary Hypertension (PPH, MIM 178600) is a rare (1 in 10^5 to 10^6) autosomal dominant disorder with reduced penetrance that has been mapped to a 3-centimorgan region on chromosome 2q34 (*PPH1* locus) (Morse et al. 1996; 30 Morse et al. 1997; Nichols et al. 1997; Deng et al. 2000).

-2-

It is characterized by monoclonal plexiform lesions of proliferating endothelial cells in pulmonary arterioles (Lee et al. 1998) that lead to elevated pulmonary artery pressures, right ventricular failure, and death (Rich et al. 5 1987). The disease can occur from infancy throughout life with a mean age of onset of 36 years and has a 2:1 ratio of affected females to males. Without intervention, the median survival is less than three years after diagnosis (D'Alonzo et al. 1991), although recent advances, such as long-term 10 prostacyclin therapy (Barst et al. 1996) and transplantation (Pasque et al. 1995) have significantly improved the quality of life and survival in some patients. Although FPPH is rare, cases secondary to known etiologies are more common and include those associated with the appetite suppressant drugs, 15 including phentermine-fenfluramine (Douglas et al. 1981; Abenhaim et al. 1996).

-3-

Summary of the Invention

This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises (1) obtaining a suitable sample from the subject; (2) detecting in the sample a bone morphogenetic protein receptor-II mutation which is not present in wildtype bone morphogenetic protein receptor-II, wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease.

10

This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises:

- 15 a) obtaining a suitable nucleic acid sample from the subject; and
- b) detecting in the nucleic acid the presence of a mutation in a gene which encodes bone morphogenetic protein receptor-II,

wherein the presence of a mutation indicates that the subject
20 is predisposed to or afflicted with the pulmonary disease.

In one embodiment of the subject invention, the pulmonary disease is Primary Pulmonary Hypertension. In one embodiment of the subject invention, the Primary Pulmonary Hypertension
25 is Familial Primary Pulmonary Hypertension.

This invention provides a method of predicting an increased likelihood of a subject's giving birth to twins or triplets which comprises:

- 30 a) obtaining a suitable nucleic acid sample from the

-4-

- subject;
- b) detecting the presence of one copy of a mutant gene which encodes bone morphogenetic protein receptor-II, thereby indicating that the subject is heterozygous for
5 the mutation,
wherein heterozygosity predicts an increased likelihood of the subject giving birth to twins or triplets.

This invention provides a method of predicting an increased
10 likelihood of a subject having a miscarriage prior to giving birth to a child which comprises:

- a) obtaining a suitable nucleic acid sample from the subject;
- b) detecting the presence of two copies of a mutant gene
15 which encodes bone morphogenetic protein receptor-II, thereby indicating that the subject is homozygous for the mutation,

wherein homozygosity predicts an increased likelihood of the subject having a miscarriage prior to giving birth to a
20 child.

This invention provides a method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises introducing a nucleic acid comprising a gene
25 encoding wildtype bone morphogenetic protein receptor-II protein into a suitable cell under conditions such that the nucleic acid expresses the wildtype bone morphogenetic protein receptor-II protein so as to thereby prevent and/or treat Familial Primary Pulmonary Hypertension in the subject.

-5-

This invention provides a method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises administering to the subject an amount of wildtype bone morphogenetic protein receptor-II effective to
5 prevent and/or treat Familial Primary Pulmonary Hypertension so as to thereby prevent and/or treat Familial Primary Pulmonary Hypertension in the subject.

This invention provides a method of detecting whether a
10 subject is either predisposed to or afflicted with Familial Primary Pulmonary Hypertension which comprises:

- a) obtaining a suitable nucleic acid sample from the subject; and
- b) detecting the presence of a (GGC)₁₂ trinucleotide repeat at
15 the 5' end of the bone morphogenetic protein receptor-II gene at positions 928 to 963,
wherein the presence of the trinucleotide repeat indicates that the subject is either predisposed to or afflicted with Familial Primary Pulmonary Hypertension.

20

This invention provides a method of screening for a compound capable of treating Familial Primary Pulmonary Hypertension which comprises:

- a) contacting a cell which expresses a mutant bone morphogenetic protein receptor-II with the compound; and
- b) determining whether the compound is capable of reversing the functional deficit in Familial Primary Pulmonary Hypertension,

wherein a reversal of the functional deficit indicates that
30 the compound is capable of treating Familial Primary

-6-

Pulmonary Hypertension.

This invention provides a method of obtaining a composition which comprises:

- 5 a) identifying a compound capable of treating Familial Primary Pulmonary Hypertension by the above method; and
 b) admixing the compound so identified or a homolog or derivative thereof with a carrier.

- 10 This invention provides a transgenic animal which comprises a mutation in a gene which encodes a bone morphogenetic protein receptor-II.

-7-

Brief Description of the Figures

Figure 1

Intron/Exon boundaries of the human BMPR2 gene. The
5 nucleotide sequence of all intron/exon boundaries and the
known size of each exon and approximate size of each intron
are shown.

Figure 2

10 Intron/Exon structure of the human BMPR2 gene. Intron and
exon sizes are as indicated. Mutations that cause premature
termination of BMPR2 are shown as closed arrows. Open arrows
indicate mutations in Arg491. The transmembrane and kinase
domains are encoded by the indicated exons.
15

Figure 3

Sequence alignment of the type-II TGF- β superfamily receptors
surrounding R491 in BMPR-II. The mutation in families
PPH001, 008 and 021 was aligned with all known type-II
20 receptors (over 50) and 14 of these are displayed.
Abbreviations: BMPR-II, bone morphogenetic protein type II
receptor; TGFR-II, transforming growth factor beta receptor
type II; ActR-II, Activin receptor type II; AMHR-II, anti-
mullerian hormone type II receptor; DAF-4, development
25 regulatory growth factor-4; XSTK3, *Xenopus* activin receptor.

Figure 4

BMPR2 mutations observed in PPH. DNA sequences are referenced
to GENE BANK BMPR2 cDNA sequence number NM_001204. These
30 sequences are also set forth in Figure 5. #A/#C/#U is the

-8-

number of affected known carrier or unaffected individuals in each family or set of families. Nomenclature: fs denotes a frameshift mutation; X1 denotes a one amino acid tail after the frameshift.

5

Figure 5

Nucleic acid and amino acid sequences for wildtype BMPR2. The nucleic acid sequence is also set forth in SEQ ID NO:1. The amino acid sequence is also set forth in SEQ ID NO:2.

10

-9-

Detailed Description of the Invention

This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises (1) obtaining a suitable sample from the subject; (2) detecting in the sample a bone morphogenetic protein receptor-II mutation which is not present in wildtype bone morphogenetic protein receptor-II, wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease.

In one embodiment, the suitable sample is a nucleic acid sample, and the mutation is detected in a nucleic acid encoding bone morphogenetic protein receptor-II. In one embodiment, the suitable sample is one which comprises a bone morphogenetic protein receptor-II polypeptide, and the mutation is detected in the bone morphogenetic protein receptor-II polypeptide.

In one embodiment, the suitable sample is a nucleic acid sample. Accordingly, one may detect a mutation in the nucleic acid. Such nucleic acid may be a DNA or RNA. In one embodiment, the sample is a protein or polypeptide sample. Accordingly, one may detect a mutation in the encoded protein or polypeptide. For example, one may detect a mutation in bone morphogenetic protein receptor-II polypeptide, such as a mutation in the amino acid sequence.

This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a

-10-

pulmonary disease which comprises:

- a) obtaining a suitable nucleic acid sample from the subject; and
- b) detecting in the nucleic acid the presence of a mutation
5 in a gene which encodes bone morphogenetic protein receptor-II,

wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease.

10 One skilled in the art would know various methods for detecting a mutation on the nucleic acid level. For example, one may use a nucleic acid probe which binds to a target nucleic acid. Such nucleic acid probe may be one which is detectable. For example, the detectable nucleic acid may be
15 labeled with a detectable marker. Such markers include but are not limited to a radioactive, a colorimetric, a luminescent, and a fluorescent label. For example, the probe may be specific for a sequence having a particular mutation (such as one of the mutations described herein), such that it
20 is capable of detecting a mutant nucleic acid. Alternatively, the probe may specific for a corresponding wildtype sequence for a particular mutation, such that it is capable of detecting a wildtype nucleic acid (i.e. one which is wildtype with respect to the mutation).

25

In various embodiments, the nucleic acid probe included but is not limited to nucleic acids which are at least 5, nucleotides in length, at least 10, nucleotides in length, at least 15, nucleotides in length, at least 20 nucleotides in
30 length, at least 25 nucleotides in length, an at least 30

-11-

nucleotides in length. The subject invention also encompasses other lengths of nucleic acid probes. In one embodiment the nucleic acid and/or nucleic acid probe is DNA. In another embodiment the nucleic acid and/or nucleic acid probe is
5 RNA.

One skilled in the art would know various conditions under which the hybridization may take place. For example, high stringency hybridization conditions may be selected at about
10 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the salt concentration is at least about 0.02 molar at pH 7 and the temperature is at least about 60°C. As other
15 factors may significantly affect the stringency of hybridization, including, among others, base composition and size of the complementary strands, the presence of organic solvents, i.e. salt or formamide¹⁷ concentration, and the extent of base mismatching, the combination of parameters is
20 more important than the absolute measure of any one. For example, high stringency may be attained by overnight hybridization at about 68°C in a 6X SSC solution, washing at room temperature with 6X SSC solution, followed by washing at about 68°C in a 0.6X SSC solution.
25

Hybridization with moderate stringency may be attained for example by: 1) filter pre-hybridizing and hybridizing with a solution of 3X SSC, 50% formamide, 0.1M Tris buffer at pH 7.5, 5X Denhardt's solution; 2.) pre-hybridization at 37°C
30 for 4 hours; 3) hybridization at 37°C with amount of labeled

-12-

probe equal to 3,000,000 cpm total for 16 hours; 4) wash in 4x SSC and 0.1% SDS solution; 5) wash 4X for 1 minute each at room temperature in 4X SSC at 60°C for 30 minutes each; and 6) dry and expose to film.

5

- Nucleic acid probe technology is well known to those skilled in the art who readily appreciate that such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate 10 detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule having the full-length or a fragment of the isolated nucleic acid molecule of the DNA virus into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable 15 bacterial host cells, replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.
- 20 RNA probes may be generated by inserting the full length or a fragment of the isolated nucleic acid molecule of the DNA virus downstream of a bacteriophage promoter such as T3, T7 or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with a linearized isolated 25 nucleic acid molecule of the DNA virus or its fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.

As defined herein nucleic acid probes may be DNA or RNA 30 fragments. DNA fragments can be prepared, for example, by

-13-

digesting plasmid DNA, or by use of PCR, or synthesized by either the phosphoramidite method described by Beaucage and Carruthers, 1981, *Tetrahedron Lett.* 22, 1859-1862 or by the triester method according to Matteucci et al., 1981, *Am. 5 Chem. Soc.* 103:3185. A double stranded fragment may then be obtained, if desired, by annealing the chemically synthesized single strands together under appropriate conditions or by synthesizing the complementary strand using DNA polymerase with an appropriate primer sequence. Where a specific 10 sequence for a nucleic acid probe is given, it is understood that the complementary strand is also identified and included. The complementary strand will work equally well in situations where the target is a double-stranded nucleic acid. It is also understood that when a specific sequence is 15 identified for use a nucleic probe, a subsequence of the listed sequence which is 25 base pairs (bp) or more in length is also encompassed for use as a probe.

Another way to detect a mutation on the nucleic acid level is 20 to perform nucleic acid sequencing on the nucleic acid sample obtained from the subject. For example, one may perform DNA sequencing to detect the presence of the mutation. One skilled in the art know how to sequence a particular nucleic acid. Examples of such sequencing methods include The Maxam 25 and Gilbert method and the Sanger method, both of which are described in Recombinant DNA, Second Edition by James Watson et al (1992), Scientific American Books the contents of which are hereby incorporated by reference.

30 If a particular mutation results in the gain and/or loss of

-14-

particular restriction cleavage sites, one may also perform a restriction digest on the nucleic acid to determine if a particular mutation is present.

5 On may also detect a mutation at the polypeptide or protein level. This invention provides a method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises:

- 10 a) obtaining a suitable sample of bone morphogenetic protein receptor-II polypeptide from the subject; and
 - b) detecting the presence of a mutation in the bone morphogenetic protein receptor-II polypeptide,
- wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease.

15

For example, may use a detectable antibody capable of binding to an epitope which is present in the mutant protein but not present in the wildtype protein. The binding of the antibody to the protein indicates a mutant protein and therefore, that 20 the subject is predisposed to or afflicted with the pulmonary disease. One may use a detectable antibody capable of binding to an epitope which is present in the wildtype protein but not present in the mutant protein. Binding of the antibody to the protein indicates a wildtype protein.

25

If a mutation results in a nonconservative mutation, such as a positively charged amino acid for a negatively charged amino acid, such mutation may be identified by running the protein in a gel to determine a difference in charge. One 30 skilled in the art would know how to identify a

-15-

nonconservative mutation.

For mutations which result in truncated proteins, such as the introduction of a stop codon or a frameshift mutation which
5 results in a truncation, such mutations may be identified by detecting the truncated protein, such as by running the protein on a gel and determining its size based on the distance that it moves within the gel.

- 10 In one embodiment, the pulmonary disease is Primary Pulmonary Hypertension. In one embodiment of the subject invention, the Primary Pulmonary Hypertension is Familial Primary Pulmonary Hypertension.
- 15 As used herein, "subject" means any animal or artificially modified animal. The subjects include but are not limited to a human being, a primate, an equine, an ovine, an avian, a bovine, a porcine, a canine, a feline or a mouse. Artificially modified animals include, but are not limited
20 to, SCID mice with human immune systems. The animals include but are not limited to mice, rats, dogs, guinea pigs, ferrets, rabbits, and primates. In the preferred embodiment, the subject is a human being.
- 25 In one embodiment, a bone morphogenetic protein receptor-II polypeptide is encoded by a gene which is located on chromosome 2q34.

In one embodiment, a wildtype nucleic acid encoding a bone
30 morphogenetic protein receptor-II polypeptide comprises

-16-

consecutive nucleotides comprising the nucleic acid sequence set forth in SEQ ID NO: 1.

In one embodiment, a wildtype bone morphogenetic protein
5 receptor-II polypeptide comprises consecutive amino acids comprising the amino acid sequence set forth in SEQ ID NO: 2.

In one embodiment, the mutation results in a truncated bone morphogenetic protein receptor-II.

10

In one embodiment, the mutated nucleic acid comprises a deletion of a nucleotide segment guanosine-guanosine-guanosine-guanosine-adenosine located at positions 1099-1103 in a wildtype nucleic acid, which wildtype nucleic acid
15 comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a glutamic acid residue located at position 368 in the wildtype polypeptide, which wildtype polypeptide comprises the amino
20 acid sequence set forth in SEQ ID NO:2. As exemplified in Figure 4, in one embodiment, the mutant protein has an amino acid tail which is one amino acid in length from the mutation at position 368, i.e. such mutant protein is terminated or truncated one amino acid from the frameshift mutation.

25

In one embodiment, the mutated nucleic acid comprises a deletion of a thymidine residue located at position 2579 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one
30 embodiment, the mutated bone morphogenetic protein receptor-

-17-

II polypeptide comprises a frameshift mutation at an asparagine residue located at position 861 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2. As exemplified in 5 Figure 4, in one embodiment, the mutant protein has an amino acid tail which is ten amino acids in length from the mutation at position 861, i.e. such mutant protein is terminated or truncated ten amino acids from the frameshift mutation.

10

In one embodiment, the mutated nucleic acid comprises a replacement of a nucleotide segment cytosine-thymidine-thymidine-thymidine located at positions 507-510 in a wildtype nucleic acid with a nucleotide segment adenosine-15 adenosine-adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position 169 in a wildtype polypeptide to a termination codon, which wildtype 20 polypeptide comprises the sequence set forth in SEQ ID NO:2. Such mutation is exemplified in Figure 4.

In one embodiment, the mutated nucleic acid comprises a mutation of a cytosine located at position number 2617 in a 25 wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position 873 in a wiltype polypeptide to a termination codon, 30 which wildtype polypeptide comprises the sequence set forth

-18-

in SEQ ID NO:2. Such mutation is exemplified in Figure 4.

In one embodiment, the mutated nucleic acid comprises a replacement of a nucleotide segment adenosine-guanosine 5 present at positions 690-691 in a wildtype nucleic acid with a thymidine residue, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a lysine residue located 10 at position 230 in a wildtype polypeptide, which wildtype polypeptide comprises the sequence set forth in SEQ ID NO:2. As exemplified in Figure 4, in one embodiment, the mutant protein has an amino acid tail which is twenty one amino acids in length from the mutation at position 230, i.e. such 15 mutant protein is terminated or truncated twenty one amino acids from the frameshift mutation.

In one embodiment, the mutation is a missense mutation.

- 20 In one embodiment, the mutated nucleic acid comprises a mutation of a cytosine located at position number 1471 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor- 25 II polypeptide comprises a mutation of an arginine located at position 491 in a wildtype polypeptide to a tryptophan, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2. Such mutation is exemplified in Figure 4.
- 30 In one embodiment, the mutated nucleic acid comprises a

-19-

mutation of a guanosine located at position number 1472 in a wildtype nucleic acid to an adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position number 491 in a wildtype polypeptide to a glutamine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2. Such mutation is exemplified in Figure 4.

10

In one embodiment, the mutated nucleic acid comprises a deletion of a nucleotide segment adenosine-thymidine-thymidine-thymidine located at positions 1248-1251 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an phenylalanine located at position number 417 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2. Such mutation is exemplified in Figure 4.

In one embodiment, the mutated nucleic acid comprises a mutation of a cytosine located at position number 994 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position number 332 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth

-20-

in SEQ ID NO:2.

- In one embodiment, the mutated nucleic acid comprises a
5 mutation of a thymidine located at position number 295 in a
wildtype nucleic acid to a cytosine, which wildtype nucleic
acid comprises the sequence set forth in SEQ ID NO:1. In one
embodiment, the mutated bone morphogenetic protein receptor-
II polypeptide comprises a mutation of a cysteine located at
10 position number 99 in a wildtype polypeptide to an arginine,
which wildtype polypeptide has the sequence set forth in SEQ
ID NO:2.
- 15 In one embodiment, the mutated nucleic acid comprises a
deletion of a guanosine residue located at position 1097 in
a wildtype nucleic acid, which wildtype nucleic acid
comprises the sequence set forth in Seq ID NO:1. In one
embodiment, the mutated bone morphogenetic protein receptor-
20 II polypeptide comprises a frameshift mutation at a proline
residue located at position 366 in the wildtype polypeptide,
which wildtype polypeptide comprises the amino acid sequence
set forth in SEQ ID NO:2. As exemplified in Figure 4, in one
embodiment, the mutant protein has an amino acid tail which
25 is 8 amino acids in length from the mutation at position 366,
i.e. such mutant protein is terminated or truncated 8 amino
acids from the frameshift mutation.
- 30 In one embodiment, the mutated nucleic acid comprises a

-21-

- mutation of a guanosine located at position number 727 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a glutamic acid located at position number 243 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
- 10 In one embodiment, the mutated nucleic acid comprises a deletion of an adenosine residue located at position 1214 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in Seq ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at an aspartic acid residue located at position 405 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2. As exemplified in Figure 4, in one embodiment, the mutant protein has an amino acid tail which is 6 amino acids in length from the mutation at position 405, i.e. such mutant protein is terminated or truncated 6 amino acids from the frameshift mutation.
- 25 In one embodiment, the mutated nucleic acid comprises a deletion of a nucleotide segment adenosine-cytosine located at positions 2441-2442 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift

-22-

mutation at a histidine residue located at position 814 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2. As exemplified in Figure 4, in one embodiment, the mutant protein has an amino acid tail which is 2 amino acids in length from the mutation at position 814, i.e. such mutant protein is terminated or truncated 2 amino acids from the frameshift mutation.

10

In one embodiment, the mutated nucleic acid comprises a mutation of a cytosine located at position number 2695 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position number 899 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

20

In one embodiment, the mutated nucleic acid comprises a deletion of a nucleotide segment present at positions 189-209 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a deletion of an amino acid segment serine-threonine-cysteine-tyrosine-glycine-leucine-tryptophan located at position numbers 64-70 in a wildtype polypeptide, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

-23-

In one embodiment, the mutated nucleic acid comprises a mutation of a guanosine located at position number 296 in a wildtype nucleic acid to a adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one
5 embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 99 in a wildtype polypeptide to a tyrosine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

10

In one embodiment, the mutated nucleic acid comprises a mutation of a thymidine located at position number 250 in a wildtype nucleic acid to a cytosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one
15 embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 84 in a wildtype polypeptide to an arginine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

20

In one embodiment, the mutated nucleic acid comprises a mutation of a guanosine located at position number 1040 in a wildtype nucleic acid to a adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1. In one
25 embodiment, the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 347 in a wildtype polypeptide to a tyrosine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

30

-24-

As used herein, the following standard abbreviations are used throughout the specification to indicate specific amino acids: A=ala=alanine; R=arg=arginine; N=asn=asparagine D=asp=aspartic acid; C=cys=cysteine; Q=gln=glutamine; 5 E=glu=glutamic acid; G=gly=glycine; H=his=histidine; I=ile=isoleucine; L=leu=leucine; K=lys=lysine; M=met=methionine; F=phe=phenylalanine; P=pro=proline; S=ser=serine; T=thr=threonine; W=trp=tryptophan; Y=tyr=tyrosine; and V=val=valine.

10

As used herein, the following standard abbreviations are used throughout the specification to indicate specific nucleotides: C=cytosine; A=adenosine; T=thymidine; and G=guanosine.

15

In one embodiment, the invention comprises detecting at least one of the mutations described herein. In one embodiment, the invention comprises detecting at least two of the mutations described herein. In one embodiment, the invention comprises 20 detecting at least three of the mutations described herein. In one embodiment, the invention comprises detecting at least four of the mutations described herein. In one embodiment, the invention comprises detecting at least five of the mutations described herein. In one embodiment, the invention comprises 25 detecting at least six of the mutations described herein. In one embodiment, the invention comprises detecting at least seven of the mutations described herein.

One skilled in the art would know various methods for 30 detecting a mutation described herein in the subject.

-25-

In one embodiment of the subject invention, the subject is suffering from an asthmatic symptom, so as to thereby prevent a subject afflicted with Familial Primary Pulmonary Hypertension from being misdiagnosed as asthmatic.

5

In one embodiment of the subject invention, the asthmatic symptom is wheezing or intermittent shortness of breath.

This invention provides a method of predicting an increased 10 likelihood of a subject giving birth to twins or triplets which comprises:

- a) obtaining a suitable nucleic acid sample from the subject;
- b) detecting the presence of one copy of a mutant 15 nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide, thereby indicating that the subject is heterozygous for the mutation, wherein heterozygosity predicts an increased likelihood of the subject giving birth to twins or triplets.

20

This invention provides a method of predicting an increased likelihood of a subject having a miscarriage prior to giving birth to a child which comprises:

- a) obtaining a suitable nucleic acid sample from the subject;
- b) detecting the presence of two copies of a mutant 25 nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide, thereby indicating that the subject is homozygous for the mutation, wherein homozygosity predicts an increased likelihood 30

-26-

of the subject having a miscarriage prior to giving birth to a child.

This invention provides a method of preventing and/or
5 treating Familial Primary Pulmonary Hypertension in a subject which comprises introducing a nucleic acid comprising a gene encoding wildtype bone morphogenetic protein receptor-II protein into a suitable cell under conditions such that the nucleic acid expresses the wildtype bone morphogenetic
10 protein receptor-II protein so as to thereby prevent and/or treat Familial Primary Pulmonary Hypertension in the subject. This invention provides a method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises introducing a nucleic acid encoding a
15 wildtype bone morphogenetic protein receptor-II polypeptide operably linked to a promotor into a suitable cell under conditions such that the nucleic acid expresses the wildtype bone morphogenetic protein receptor-II protein so as to thereby prevent and/or treat Familial Primary Pulmonary
20 Hypertension in the subject. In one embodiment of the subject invention, the suitable cell is a lung cell.

As used herein, "treating" means either slowing, stopping or reversing the progression of the disorder. In the preferred
25 embodiment, "treating" means reversing the progression to the point of eliminating the disorder. As used herein, "preventing" means that the subject will not become afflicted with the disorder.

30 In one embodiment, a vector comprises the nucleic acid.

-27-

Vectors which may be used in the methods of the present invention are viral including adenoviruses, retroviral, vectors, adeno-associated viral (AAV) vectors.

- 5 The viral vector selected should meet the following criteria:
 - 1) the vector must be able to infect the cell of interest and thus viral vectors having an appropriate host range must be selected; 2) the transferred gene should be capable of persisting and being expressed in a cell for an extended period of time; and 3) the vector should be safe to the host and cause minimal cell transformation. Retroviral vectors and adenoviruses offer an efficient, useful, and presently the best-characterized means of introducing and expressing foreign genes efficiently in mammalian cells. These vectors have very broad host and cell type ranges, express genes stably and efficiently. The safety of these vectors has been proved by many research groups. In fact many are in clinical trials.
 - 10
 - 15
- 20 Other virus vectors that may be used for gene transfer into cells for correction of disorders include retroviruses such as Moloney murine leukemia virus (MoMuLV); papovaviruses such as JC, SV40, polyoma, adenoviruses; Epstein-Barr Virus (EBV); papilloma viruses, e.g. bovine papilloma virus type I (BPV);
- 25 vaccinia and poliovirus and other human and animal viruses.

Adenoviruses have several properties that make them attractive as cloning vehicles (Bachettis et al.: Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA. PNAS USA, 1977 74:1590; Berkner, K.

30

-28-

L.: Development of adenovirus vectors for expression of heterologous genes. Biotechniques, 1988 6:616; Ghosh-Choudhury G., et al., Human adenovirus cloning vectors based on infectious bacterial plasmids. Gene 1986; 50:161; Hag-
5 Ahmand Y., et al., Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J Virol 1986; 57:257;
Rosenfeld M., et al., Adenovirus-mediated transfer of a recombinant .alpha..sub.1 -antitrypsin gene to the lung
10 epithelium in vivo. Science 1991; 252:431).

For example, adenoviruses possess an intermediate sized genome that replicates in cellular nuclei; many serotypes are clinically innocuous; adenovirus genomes appear to be stable
15 despite insertion of foreign genes; foreign genes appear to be maintained without loss or rearrangement; and adenoviruses can be used as high level transient expression vectors with an expression period up to 4 weeks to several months. Extensive biochemical and genetic studies suggest that it is
20 possible to substitute up to 7-7.5 kb of heterologous sequences for native adenovirus sequences generating viable, conditional, helper-independent vectors (Kaufman R. J.; identification of the component necessary for adenovirus translational control and their utilization in cDNA
25 expression vectors. PNAS USA, 1985 82:689).

AAV is a small human parvovirus with a single stranded DNA genome of approximately 5 kb. This virus can be propagated as an integrated provirus in several human cell types. AAV
30 vectors have several advantage for human gene therapy. For

-29-

- example, they are tropic for human cells but can also infect other mammalian cells; (2) no disease has been associated with AAV in humans or other animals; (3) integrated AAV genomes appear stable in their host cells; (4) there is no
5 evidence that integration of AAV alters expression of host genes or promoters or promotes their rearrangement; (5) introduced genes can be rescued from the host cell by infection with a helper virus such as adenovirus.

10 HSV-1 vector system facilitates introduction of virtually any gene into non-mitotic cells (Geller et al. an efficient deletion mutant packaging system for a defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology. PNAS USA, 1990 87:8950).

15

Another vector for mammalian gene transfer is the bovine papilloma virus-based vector (Sarver N, et al., Bovine papilloma virus DNA: A novel eukaryotic cloning vector. Mol Cell Biol 1981; 1:486).

20

Vaccinia and other poxvirus-based vectors provide a mammalian gene transfer system. Vaccinia virus is a large double-stranded DNA virus of 120 kilodaltons (kd) genomic size (Panicali D, et al., Construction of poxvirus as cloning
25 vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccine virus. Proc Natl Acad Sci USA 1982; 79:4927; Smith et al. infectious vaccinia virus recombinants that express hepatitis B virus surface antigens. Nature, 1983 302:490.)

30

-30-

Retroviruses are packages designed to insert viral genes into host cells (Guild B, et al., Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo. J Virol 5 1988; 62:795; Hock R. A., et al., Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells. Nature 1986; 320:275).

The basic retrovirus consists of two identical strands of RNA 10 packaged in a proviral protein. The core surrounded by a protective coat called the envelope, which is derived from the membrane of the previous host but modified with glycoproteins contributed by the virus.

15 Markers and amplifiers can also be employed in the subject expression systems. A variety of markers are known which are useful in selecting for transformed cell lines and generally comprise a gene whose expression confers a selectable phenotype on transformed cells when the cells are grown in an 20 appropriate selective medium. Such markers for mammalian cell lines include, for example, the bacterial xanthine-guanine phosphoribosyl transferase gene, which can be selected for in medium containing mycophenolic acid and xanthine (Mulligan et al. (1981) Proc. Natl. Acad. Sci. USA 78:2072-2076), and the 25 aminoglycoside phosphotransferase gene (specifying a protein that inactivates the antibacterial action of neomycin/kanamycin derivatives), which can be selected for using medium containing neomycin derivatives such as G418 which are normally toxic to mammalian cells (Colbere-Garapin 30 et al. (1981) J. Mol. Biol. 150:1-14). Useful markers for

-31-

other eucaryotic expression systems, are well known to those of skill in the art.

Infection can be carried out in vitro or in vivo. In vitro infection of cells is performed by adding the gene transfer 5 vectors to the cell culture medium. When infection is carried out in vivo, the solution containing the gene transfer vectors may be administered by a variety of modes, depending on the tissue which is to be infected. Examples of such modes of administration include injection of gene transfer 10 vectors into the skin, topical application onto the skin, direct application to a surface of epithelium, or instillation into an organ (e.g., time release patch or capsule below the skin or into a tumor).

15 Expression can be amplified by placing an amplifiable gene, such as the mouse dihydrofolate reductase (dhfr) gene adjacent to the coding sequence. Cells can then be selected for methotrexate resistance in dhfr-deficient cells. See, e.g. Urlaub et al. (1980) Proc. Natl. Acad. Sci. USA 77:4216-
20 4220; Rungold et al. (1981) J. Mol. and Appl. Genet. 1:165-175.

The above-described system can be used to direct the expression of a wide variety of procaryotic, eucaryotic and viral proteins, including, for example, viral glycoproteins 25 suitable for use as vaccine antigens, immunomodulators for regulation of the immune response, hormones, cytokines and growth factors, as well as proteins useful in the production of other biopharmaceuticals.

It may also be desirable to produce mutants or analogs of the proteins of interest. Mutants or analogs may be prepared by the deletion of a portion of the sequence encoding the 5 protein, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., *supra*; DNA Cloning, Vols. I and II, 10 *supra*; Nucleic Acid Hybridization, *supra*.

It certain embodiments, it may be desirable to further engineer the coding sequence to effect secretion of the polypeptide from the host organism. This enhances clone 15 stability and prevents the toxic build up of proteins in the host cell so that expression can proceed more efficiently. Homologous signal sequences can be used for this purpose with proteins normally found in association with a signal sequence. Additionally, heterologous leader sequences which 20 provide for secretion of the protein can be added to the constructs. Preferably, processing sites will be included such that the leader fragment can be cleaved from the protein expressed therewith. (See, e.g., U.S. Pat. No. 4,336,246 for a discussion of how such cleavage sites can be introduced). 25 The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids.

In one embodiment of the invention, a heterologous gene sequence, i.e., a therapeutic gene, is inserted into the

-33-

nucleic acid molecule of the invention. Other embodiments of the isolated nucleic acid molecule of the invention include the addition of a single enhancer element or multiple enhancer elements which amplify the expression of the
5 heterologous therapeutic gene without compromising tissue specificity.

The transformation procedure used depends upon the host to be transformed. Mammalian cells can conveniently be transformed
10 using, for example, DEAE-dextran based procedures, calcium phosphate precipitation (Graham, F. L. and Van der Eb, A. J. (1973) Virology 52:456-467), protoplast fusion, liposome-mediated transfer, polybrene-mediated transfection and direct microinjection of the DNA into nuclei. Bacterial cells will
15 generally be transformed using calcium chloride, either alone or in combination with other divalent cations and DMSO (Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989)). DNA can also be introduced into bacterial cells by electroporation. Methods
20 of introducing exogenous DNA into yeast hosts typically include either the transformation of spheroplasts or transformation of intact yeast cells treated with alkali cations.

The constructs can also be used in gene therapy or nucleic acid immunization, to direct the production of the desired gene product in vivo, by administering the expression constructs directly to a subject for the in vivo translation thereof. See, e.g. EPA Publication No. 336,523 (Dreano et al., published Oct. 11, 1989). Alternatively, gene transfer

-34-

can be accomplished by transfecting the subject's cells or tissues with the expression constructs ex vivo and reintroducing the transformed material into the host. The constructs can be directly introduced into the host organism,
5 i.e., by injection (see International Publication No. WO/90/11092; and Wolff et al., (1990) Science 247:1465-1468). Liposome-mediated gene transfer can also be accomplished using known methods. See, e.g., Hazinski et al., (1991) Am. J. Respir. Cell Mol. Biol. 4:206-209; Brigham et al. (1989)
10 Am. J. Med. Sci. 298:278-281; Canonico et al. (1991) Clin. Res. 39:219A; and Nabel et al. (1990) Science 249:1285-1288. Targeting agents, such as antibodies directed against surface antigens expressed on specific cell types, can be covalently conjugated to the liposomal surface so that the nucleic acid
15 can be delivered to specific tissues and cells for local administration.

There are several protocols for human gene therapy which have been approved for use by the Recombinant DNA Advisory Committee (RAC) which conform to a general protocol of target cell infection and administration of transfected cells (see for example, Blaese, R.M., et al., 1990; Anderson, W. F., 1992; Culver, K.W. et al., 1991). In addition, U.S. Patent No. 5,399,346 (Anderson, W. F. et al., March 21, 1995, U.S.
25 Serial No. 220,175) describes procedures for retroviral gene transfer. The contents of these support references are incorporated in their entirety into the subject application. Retroviral-mediated gene transfer requires target cells which are undergoing cell division in order to achieve stable
30 integration hence, cells are collected from a subject often

-35-

by removing blood or bone marrow. It may be necessary to select for a particular subpopulation of the originally harvested cells for use in the infection protocol. Then, a retroviral vector containing the gene(s) of interest would be
5 mixed into the culture medium. The vector binds to the surface of the subject's cells, enters the cells and inserts the gene of interest randomly into a chromosome. The gene of interest is now stably integrated and will remain in place and be passed to all of the daughter cells as the cells grow
10 in number. The cells may be expanded in culture for a total of 9-10 days before reinfusion (Culver et al., 1991). As the length of time the target cells are left in culture increases, the possibility of contamination also increases, therefore a shorter protocol would be more beneficial.

15

This invention provides for the construction of a promoter or a functional equivalent thereof linked to a gene of interest for use in gene therapy or for diagnostic uses. The efficiency of transduction of these vectors can be tested in
20 cell culture systems.

This invention involves targeting a gene-of-interest to the a particular cell so that the protein encoded by the gene is expressed and directly or indirectly ameliorate the diseased
25 state.

After infecting a susceptible cell, the transgene driven by a specific promoter in the vector expresses the protein encoded by the gene. The use of the highly specific gene vector will allow selective expression of the specific genes
30 in cancer cells.

-36-

The basic tasks in the present method of the invention are isolating the gene of interest, selecting the proper vector vehicle to deliver the gene of interest to the body,
5 administering the vector having the gene of interest into the body, and achieving appropriate expression of the gene of interest. The present invention provides packaging the cloned genes, i.e. the genes of interest, in such a way that they can be injected directly into the bloodstream or relevant
10 organs of patients who need them. The packaging will protect the foreign DNA from elimination by the immune system and direct it to appropriate tissues or cells.

In one embodiment of the invention, the gene of interest
15 (desired coding sequence) is a bone morphogenetic protein receptor-II gene.

Along with the human or animal gene of interest another gene, e.g., a selectable marker, can be inserted that will allow
20 easy identification of cells that have incorporated the modified retrovirus. The critical focus on the process of gene therapy is that the new gene must be expressed in target cells at an appropriate level with a satisfactory duration of expression.

25

The methods described herein to modify vectors and administering such modified vectors into the skin are merely for purposes of illustration and are typical of those that

-37-

might be used. However, other procedures may also be employed, as is understood in the art.

Most of the techniques used to construct vectors and the like
5 are widely practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline.

10 Construction of suitable vectors containing the desired therapeutic gene coding and control sequences employs standard ligation and restriction techniques, which are well understood in the art (see Maniatis et al., in Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory,
15 New York (1982)). Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

Site-specific DNA cleavage is performed by treating with the
20 suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes (See, e.g. New England Biolabs Product Catalog). In general, about 1 µg
25 of plasmid or DNA sequences is cleaved by one unit of enzyme in about 20 µl of buffer solution. Typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate.

Incubation times of about one hour to two hours at about 37 degree. C. are workable, although variations can be tolerated. After each incubation, protein is removed by 5 extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using 10 standard techniques. A general description of size separations is found in Methods in Enzymology 65:499-560 (1980).

Restriction cleaved fragments may be blunt ended by treating 15 with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20.degree. C. to 25.degree. C. in 50 mM Tris (pH 7.6) 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 5-10 .mu.M dNTPs. The 20 Klenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the dNTPs, or with selected dNTPs, within the limitations dictated by the nature of the sticky 25 ends. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or Bal-31 results in hydrolysis of any single-stranded portion.

-39-

Ligations are performed in 10-50 μ l volumes under the following standard conditions and temperatures using T4 DNA ligase. Ligation protocols are standard (D. Goeddel (ed.) Gene Expression Technology: Methods in Enzymology (1991)). In 5 vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIP) in order to remove the 5' phosphate and prevent religation of the vector. Alternatively, religation can be 10 prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.

Suitable vectors include viral vector systems e.g. ADV, RV, 15 and AAV (R. J. Kaufman "Vectors used for expression in mammalian cells" in Gene Expression Technology, edited by D. V. Goeddel (1991)).

Many methods for inserting functional DNA transgenes into 20 cells are known in the art. For example, non-vector methods include nonviral physical transfection of DNA into cells; for example, microinjection (DePamphilis et al., BioTechnique 6:662-680 (1988)); liposomal mediated transfection (Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987), 25 Felgner and Holm, Focus 11:21-25 (1989) and Felgner et al., Proc. West. Pharmacol. Soc. 32: 115-121 (1989)) and other methods known in the art.

-40-

One way to get DNA into a target cell is to put it inside a membrane bound sac or vesicle such as a spheroplast or liposome, or by calcium phosphate precipitation (CaPO₄ sub.4) (Graham F. and Van der Eb, A., Virology 52:456 1973; 5 Schaefer-Ridder M., et al., Liposomes as gene carriers: Efficient transduction of mouse L cells by thymidine kinase gene. Science 1982; 215:166; Stavridis J. C., et al., Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in 10 rabbits. Exp Cell Res 1986; 164:568-572).

A vesicle can be constructed in such a way that its membrane will fuse with the outer membrane of a target cell. The vector of the invention in vesicles can home into the cancer 15 cells.

The spheroplasts are maintained in high ionic strength buffer until they can be fused through the mammalian target cell using fusogens such as polyethylene glycol.

20

Liposomes are artificial phospholipid vesicles. Vesicles range in size from 0.2 to 4.0 micrometers and can entrap 10% to 40% of an aqueous buffer containing macromolecules. The liposomes protect the DNA from nucleases and facilitate its 25 introduction into target cells. Transfection can also occur through electroporation.

Before administration, the modified vectors may be suspended

-41-

in complete PBS at a selected density for injection. In addition to PBS, any osmotically balanced solution which is physiologically compatible with the subject may be used to suspend and inject the modified vectors into the host.

5

For injection, the cell suspension is drawn up into the syringe and administered to anesthetized recipients. Multiple injections may be made using this procedure. The viral suspension procedure thus permits administration of 10 genetically modified vectors to any predetermined site in the skin, is relatively non-traumatic, allows multiple administrations simultaneously in several different sites or the same site using the same viral suspension. Multiple injections may consist of a mixture of therapeutic genes.

15

Expression of a gene is controlled at the transcription, translation or post-translation levels. Transcription initiation is an early and critical event in gene expression. This depends on the promoter and enhancer sequences and is 20 influenced by specific cellular factors that interact with these sequences. The transcriptional unit of many prokaryotic genes consists of the promoter and in some cases enhancer or regulator elements (Banerji et al., Cell 27:299 (1981); Corden et al., Science 209:1406 (1980); and Breathnach and 25 Chambon, Ann. Rev. Biochem. 50:349 (1981)).

For retroviruses, control elements involved in the replication of the retroviral genome reside in the long terminal repeat (LTR) (Weiss et al., eds., In: The molecular

-42-

biology of tumor viruses: RNA tumor viruses, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982)).

Moloney murine leukemia virus (MLV) and Rous sarcoma virus
5 (RSV) LTRs contain promoter and enhancer sequences (Jolly et al., Nucleic Acids Res. 11:1855 (1983); Capecchi et al., In: Enhancer and eukaryotic gene expression, Gulzman and Shenk, eds., pp. 101-102, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y.).

10

Promoter and enhancer regions of a number of non-viral promoters have also been described (Schmidt et al., Nature 314:285 (1985); Rossi and de Crombrugghe, Proc. Natl. Acad. Sci. USA 84:5590-5594 (1987)).

15

In addition to using viral and non-viral promoters to drive therapeutic gene expression, an enhancer sequence may be used to increase the level of therapeutic gene expression. Enhancers can increase the transcriptional activity not only
20 of their native gene but also of some foreign genes (Armelor, Proc. Natl. Acad. Sci. USA 70:2702 (1973)).

Therapeutic gene expression may also be increased for long term stable expression after injection using cytokines to
25 modulate promoter activity.

The methods of the invention are exemplified by preferred embodiments in which modified vectors carrying a therapeutic

-43-

gene are injected intracerebrally into a subject.

The most effective mode of administration and dosage regimen for the molecules of the present invention depends upon the
5 exact location of the disease being treated, the severity and course of the disease, the subject's health and response to treatment and the judgment of the treating physician. Accordingly, the dosages of the molecules should be titrated to the individual subject. The molecules may be delivered
10 directly or indirectly via another cell, autologous cells are preferred, but heterologous cells are encompassed within the scope of the invention.

The interrelationship of dosages for animals of various sizes and species and humans based on mg/m.² of surface area is
15 described by Freireich, E. J., et al. Cancer Chemother., Rep. 50 (4):219-244 (1966). Adjustments in the dosage regimen may be optimized, e.g., doses may be divided and administered on a daily basis or the dose reduced proportionally depending upon the situation (e.g., several divided dose may be
20 administered daily or proportionally reduced depending on the specific therapeutic situation).

It would be clear that the dose of the molecules of the invention required to achieve cures may be further reduced
25 with schedule optimization.

Liposomes could be used as a delivery agent to introduce the nucleic acid construct to the cells of the subject to be treated. Of course, there are many ways to deliver such a

-44-

nucleic acid construct which would be known to one of skill in the art (e.g. microinjection; topical application; use of a chemical vehicle; direct injection into the tumor; etc.).

- 5 This invention provides a method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises administering to the subject an amount of wildtype bone morphogenetic protein receptor-II effective to prevent and/or treat Familial Primary Pulmonary Hypertension
- 10 so as to thereby prevent and/or treat Familial Primary Pulmonary Hypertension in the subject. This invention provides a method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises administering to the subject an effective amount of a
- 15 wildtype bone morphogenetic protein receptor-II polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2 to prevent and/or treat Familial Primary Pulmonary Hypertension in the subject.

20

As used herein, "administering" may be effected or performed using any of the methods known to one skilled in the art. The compound may be administered by various routes including but

25 not limited to aerosol, intravenous, oral or topical route. The administration may comprise intralesional, intraperitoneal, subcutaneous, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical,

-45-

intrathecal, gingival pocket, per rectum, intrabronchial, nasal, transmucosal, intestinal, oral, ocular or otic delivery. In a further embodiment, the administration includes intrabronchial administration, anal, intrathecal 5 administration or transdermal delivery. The compounds and/or agents of the subject invention may be delivered locally via a capsule which allows sustained release of the agent or the peptide over a period of time. Controlled or sustained release compositions include formulation in lipophilic depots 10 (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the agent coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific 15 receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral. The carrier includes but is not limited to 20 those which are a diluent, an aerosol, a topical carrier, an aqueous solution, a nonaqueous solution or a solid carrier.

This invention provides a method of detecting whether a subject is either predisposed to or afflicted with Familial 25 Primary Pulmonary Hypertension which comprises:

- a) obtaining a suitable nucleic acid sample from the subject; and
- b) detecting the presence of a (GGC)₁₂ trinucleotide repeat

-46-

at positions -928 to -963 in the 5' end of the bone morphogenetic protein receptor-II gene,

wherein the presence of the trinucleotide repeat indicates that the subject is either predisposed to or afflicted with

5 Familial Primary Pulmonary Hypertension.

This invention provides a method of screening for a compound capable of treating Familial Primary Pulmonary Hypertension which comprises:

10 a) contacting a cell which expresses a mutant bone morphogenetic protein receptor-II with the compound; and

b) determining whether the compound is capable of reversing the functional deficit in Familial Primary Pulmonary Hypertension,

15 wherein a reversal of the functional deficit indicates that the compound is capable of treating Familial Primary Pulmonary Hypertension. In one embodiment of the subject invention, the functional deficit is reduced kinase activity for the bone morphogenetic protein receptor-II.

20

This invention provides a method of obtaining a composition which comprises:

a) identifying a compound capable of treating Familial Primary Pulmonary Hypertension by the above method; and

25 b) admixing the compound so identified or a homolog or derivative thereof with a carrier.

-47-

In one embodiment, the compound is recovered before being admixed with a carrier.

- The carriers include but are not limited to an aerosol,
5 intravenous, oral and topical carriers. Accordingly, the invention provides the above composition adapted for aerosol, intravenous, oral or topical applications or other applications known to one skilled in the art.
- 10 This invention provides the agents, compounds and/or compositions described herein and carrier. Such carrier may be a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharmaceutically acceptable carriers may include
15 but are not limited to aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water,
20 alcoholic/aqueous solutions, emulsions or suspensions, saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte
25 replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

-48-

As used herein, "composition" means a mixture. The compositions include but are not limited to those suitable for oral, rectal, intravaginal, topical, nasal, ophthalmic, or parenteral administration to a subject. As used herein,
5 "parenteral" includes but is not limited to subcutaneous, intravenous, intramuscular, or intrasternal injections or infusion techniques. As used herein, "administering" may be effected or performed using any of the methods known to one skilled in the art. The methods for administration to the
10 subject include but are not limited to oral, rectal, intravaginal, topical, nasal, ophthalmic, parenteral subcutaneous, intravenous, intramuscular, or intrasternal injections or infusion techniques.

15 This invention provides a transgenic non-human animal whose cells comprise a mutant nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide. In one embodiment, the non-human animal exhibits primary pulmonary hypertension. In one embodiment, the nucleic acid is
20 operatively linked to a promotor. In one embodiment, the non-human animal is a mouse, a rat, a sheep, a dog, a primate or a reptile. This invention provides a transgenic mouse which comprises a mutation in a gene which encodes a bone morphogenetic protein receptor-II. In one embodiment, the
25 transgenic animal is a mouse.

Transgenics

The following U.S. Patents are hereby incorporated by

-49-

reference: U.S. Patent No. 6,025,539, IL-5 transgenic mouse; U.S. Patent No. 6,023,010, Transgenic non-human animals depleted in a mature lymphocytic cell-type; U.S. Patent No. 6,018,098, In vivo and in vitro model of cutaneous photoaging; U.S. Patent No. 6,018,097, Transgenic mice expressing human insulin; U.S. Patent No. 6,008,434, Growth differentiation factor-11 transgenic mice; U.S. Patent No. 6,002,066; H2-M modified transgenic mice; U.S. Patent No. 5,994,618, Growth differentiation factor-8 transgenic mice; U.S. Patent No. 5,986,171, Method for examining neurovirulence of polio virus, U.S. Patent No. 5,981,830, Knockout mice and their progeny with a disrupted hepsin gene; U.S. Patent No. 5,981,829, .DELTA.Nur77 transgenic mouse; U.S. Patent No. 5,936,138; Gene encoding mutant L3T4 protein which facilitates HIV infection and transgenic mouse expressing such protein; U.S. Patent No. 5,912,411, Mice transgenic for a tetracycline-inducible transcriptional activator; U.S. Patent No. 5,894,078, Transgenic mouse expressing C-100 app.

20

The methods used for generating transgenic animals, including but not limited to mice are well known to one of skill in the art. For example, one may use the manual entitled "Manipulating the Mouse Embryo" by Brigid Hogan et al. (Ed. 25 Cold Spring Harbor Laboratory) 1986.

See for example, Leder and Stewart, U.S. Patent No. 4,736,866 for methods for the production of a transgenic mouse.

-50-

For sometime it has been known that it is possible to carry out the genetic transformation of a zygote (and the embryo and mature organism which result therefrom) by the placing or insertion of exogenous genetic material into the nucleus of 5 the zygote or to any nucleic genetic material which ultimately forms a part of the nucleus of the zygote. The genotype of the zygote and the organism which results from a zygote will include the genotype of the exogenous genetic material. Additionally, the inclusion of exogenous genetic 10 material in the zygote will result in a phenotype expression of the exogenous genetic material.

The genotype of the exogenous genetic material is expressed upon the cellular division of the zygote. However, the 15 phenotype expression, e.g., the production of a protein product or products of the exogenous genetic material, or alterations of the zygote's or organism's natural phenotype, will occur at that point of the zygote's or organism's development during which the particular exogenous genetic 20 material is active. Alterations of the expression of the phenotype include an enhancement or diminution in the expression of a phenotype or an alteration in the promotion and/or control of a phenotype, including the addition of a new promoter and/or controller or supplementation of an 25 existing promoter and/or controller of the phenotype.

The genetic transformation of various types of organisms is disclosed and described in detail in U.S. Pat. No. 4,873,191, issued Oct. 10, 1989, which is incorporated herein by

-51-

reference to disclose methods of producing transgenic organisms. The genetic transformation of organisms can be used as an in vivo analysis of gene expression during differentiation and in the elimination or diminution of 5 genetic diseases by either gene therapy or by using a transgenic non-human mammal as a model system of a human disease. This model system can be used to test putative drugs for their potential therapeutic value in humans.

10 The exogenous genetic material can be placed in the nucleus of a mature egg. It is preferred that the egg be in a fertilized or activated (by parthenogenesis) state. After the addition of the exogenous genetic material, a complementary haploid set of chromosomes (e.g., a sperm cell or polar body) 15 is added to enable the formation of a zygote. The zygote is allowed to develop into an organism such as by implanting it in a pseudopregnant female. The resulting organism is analyzed for the integration of the exogenous genetic material. If positive integration is determined, the organism 20 can be used for the in vivo analysis of the gene expression, which expression is believed to be related to a particular genetic disease.

The "transgenic non-human animals" of the invention are 25 produced by introducing "transgenes" into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of

-52-

development of the embryonal target cell. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pl of 5 DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host gene before the first cleavage (Brinster, et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 4438-4442). As a consequence, all cells of 10 the transgenic non-human animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. Microinjection of zygotes is the preferred method 15 for incorporating transgenes in practicing the invention.

Retroviral infection can also be used to introduce transgene into a non-human animal. The developing non-human embryo can be cultured in vitro to the blastocyst stage. During this 20 time, the blastomeres can be targets for retroviral infection (Jaenich, R. (1976) Proc. Natl. Acad. Sci U.S.A. 73, 1260-1264). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, et al. (1986) in Manipulating the Mouse Embryo, Cold Spring 25 Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner, et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 6927-6931; Van der Putten, et al. (1985) Proc. Natl. Acad.

-53-

Sci U.S.A. 82, 6148-6152). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, supra; Stewart, et al. (1987) EMBO J. 6, 383-388). Alternatively, 5 infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoel (Jahner, D., et al. (1982) Nature 298, 623-628). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic 10 non-human animal. Further, the founder may contain various retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by 15 intrauterine retroviral infection of the midgestation embryo (Jahner, D. et al. (1982) supra).

A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre- 20 implantation embryos cultured in vitro and fused with embryos (Evans, M. J., et al. (1981) Nature 292, 154-156; Bradley, M. O., et al. (1984) Nature 309, 255-258; Gossler, et al. (1986) Proc. Natl. Acad. Sci U.S.A. 83, 9065-9069; and Robertson, et al. (1986) Nature 322, 445-448). Transgenes can be 25 efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal.

-54-

For review see Jaenisch, R. (1988) Science 240, 1468-1474.

As used herein, a "transgene" is a DNA sequence introduced into the germline of a non-human animal by way of human
5 intervention such as by way of the above described methods.

Asthma:

We have previously observed an individual who had been mis-diagnosed with asthma, but actually had PPH (Morse and
10 Barst, 1997). This was possible due to the strong suspicion of PPH because of a family history of the disease. Now that the gene for PPH at PPH1 has been identified it is possible to screen for mutations in BMPR2 in all patients who present with the symptoms of asthma to prevent mis-diagnosis and
15 mis-treatment of PPH as asthma. Symptoms of asthma include but are not limited to wheezing and intermittent shortness of breath. Screening panels of many genes that are risk factors for asthma are available to aid physicians in making the diagnosis. The PPH1 gene (BMPR2) may be included in such
20 panels to rule out PPH, a disease that can present with the symptoms of asthma. This is analogous to the present day practice of screening all persons who present with a first-break psychotic disorder for Wilson's disease, even though most of them will have schizophrenia and bipolar
25 disorder.

Twinning:

-55-

We have observed an increased rate of twinning in our collection of families. Identification of BMPR2 as PPH1 sheds light on why this may occur. It has recently been observed that sheep that have only one functional copy of the 5 ligand BMP15 (bone morphogenetic protein 15) have an increased rate of twin and triplet births (Galloway et al., 2000). BMPR2 is a receptor for BMP15 and hence having only one functional copy of the receptor in the families with PPH is directly analogous to having only one functional copy of 10 the ligand, and is likely to be responsible for the increased rate of twinning observed. Accordingly, subject of the subject invention may be a female subject, i.e. the mother, or a male subject, i.e. the father.

15 In vitro Methods for Drug Screening:

Identification of BMPR2 as PPH1 enables the design and use of in vitro methods of screening for compounds that might correct the functional deficit in the disorder. One functional deficit is reduced amount or a lack of kinase 20 activity. Cell lines are constructed that express forms of mutant BMPR2 as described herein, and the rest of the BMP signaling pathway. The function of this pathway is then assayed in vitro, with and without exogenous compounds and those that return function to normal are considered as 25 candidates as therapeutic agents for treatment of the disorder.

Pharmacogenetics:

-56-

Knowledge of BMPR2 as PPH1 enables testing of outcome and side effects to therapeutic agents on the basis of disease mutations for PPH and common polymorphisms in the BMPR2 gene and other genes of the BMP signaling pathway.

5

Mouse Models for Drug Screening:

Knowledge of BMPR2 as PPH1 enables the construction of inbred mouse strains containing the exact mutations described in this application in the highly homologous mouse gene, or 10 after disabling the mouse gene, a copy of the human gene inserted into the mouse. These inbred strains are then useful as reagents for in vivo tests of compounds that act as therapeutic agents for treatment of PPH.

15 According to one aspect, the present invention is directed to a peptide or polypeptide encoded by the mutant BMPR2 nucleic acid sequences of the invention or a fragment thereof. Another embodiment of the present invention is a purified or isolated nucleotide sequence encoding the above identified 20 mutant BMPR2 nucleic acid sequences of the invention and fragments thereof. Another embodiment is a purified or isolated nucleotide sequence which hybridizes to the polynucleotide sequence encoding the above-mentioned mutant BMPR2 nucleic acid sequences of the invention and fragments 25 thereof. One skilled in the art would be able to determine the preferred hybridization conditions.

-57-

Another embodiment is a host cell transformed with a polynucleotide

sequence encoding the above-mentioned mutant BMPR2 peptide or polypeptide sequences of the invention and fragments.

5 Transformation of a host cell with recombinant DNA may be carried out by conventional techniques known in the art. Where the host is prokaryotic, such as E. coli, competent cells which are capable of DNA uptake can be prepared from cells harvested after the exponential growth phase and 10 subsequently treated by the CaCl₂ method by procedures well known in the art. Alternatively, MgCl₂ or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

15 When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as micro-injection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be 20 cotransformed with DNA sequences encoding the mutant BMPR2 polypeptide sequences of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) 25 or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. EUKARYOTIC VIRAL VECTORS Gluzman (ed.), Cold Spring Harbor Laboratory, 1982.

-58-

Isolation and purification of the mutant BMPR2 peptide or polypeptide sequences of the invention expressed by a transformed host may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies. Antibodies provided in the present invention are immuno-reactive with the mutant BMPR2 peptides and polypeptides.

Another embodiment is a recombinant expression vector containing the above-mentioned nucleotide sequences. Preferably, the vector is a virus. Preferred viruses are RNA viruses and preferred RNA viruses are retroviruses. Another preferred vector is a liposome, preferably a target-specific liposome which may be targeted with, for example, an antibody or ligand. Another preferred vector is a plasmid.

Another embodiment is an antibody which binds to the above-mentioned peptides. The antibody may be polyclonal or monoclonal. Using the isolated peptides, antibodies are prepared which are capable of determining the presence or absence of peptide products encoded by the pulmonary hypertension-linked nucleotide sequences. One embodiment of the present invention is directed to these antibodies. Furthermore, another embodiment of the present invention is directed to antibodies which can detect individuals at risk of developing pulmonary hypertension (even in individuals who have not clinically manifested any symptoms of the disease).

-59-

Another embodiment is a method for detecting the risk of developing or for diagnosing pulmonary hypertension, preferably primary pulmonary hypertension, comprising contacting a cellular component from the subject with an antibody or nucleic acid probe which binds to a cellular component associated with the pulmonary hypertension. In one embodiment, the cellular component is taken from the subject's lung tissue and is a nucleic acid. Preferably, the nucleic acid is DNA encoding the above-mentioned disease-linked peptides or fragments. Also preferred as a nucleic acid is RNA. Another preferred cellular component is the above-mentioned peptides and fragments.

Preferably, the nucleic acid probe specifically hybridizes to the above-mentioned cellular component. When the reagent is a nucleic acid probe, it is preferably detectably labeled. Preferred labels include a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.

20

Alternatively, if the cellular component is a peptide or fragment, then an antibody is used which specifically binds to the peptide or fragment. As noted above, the antibody may be monoclonal or polyclonal.

25

Another embodiment is a method of gene therapy, comprising introducing into the cells of a host subject an expression

-60-

vector comprising a polynucleotide sequence encoding the non-mutant, "normal" BMPR2 sequence. Preferably, the expression vector is introduced into the cells of the host subject *ex vivo*, yielding transformed cells, and the 5 transformed cells then are reintroduced into the subject. A preferred expression vector for this purpose is an RNA virus, preferably a retrovirus.

Another embodiment is a kit for detecting pulmonary hypertension comprising a nucleic acid probe that binds to a polynucleotide sequence encoding one of the above-mentioned peptides or fragments. Preferably, the probe is labeled for ease of detection with a label as described above. Alternatively, the kit may comprise an antibody which 15 specifically binds to one of the above-mentioned peptides or fragments. Still another alternative is to use an oligonucleotide primer in the kit that permits amplification of a target polynucleotide sequence encoding one of the above-mentioned peptides or fragments, for example, by 20 polymerase chain reaction (PCR) amplification.

Peptides of the invention can be synthesized by the well known solid phase peptide synthesis methods described, for example, by Merrifield, J. Am. Chem. Soc. 85: 2149 (1962), 25 and by Stewart and Young, SOLID PHASE PEPTIDES SYNTHESIS 27-62 (Freeman Publ., 1969).

The polyclonal and monoclonal antibodies of the invention

-61-

are immunoreactive with the peptides or immunogenic fragments of the peptides. If desired, polyclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which peptide is bound or by utilizing common 5 peptides to selectively remove non-specific antibodies. Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct mono-clonal antibody preparations are provided. The term "antibody" as used in this invention includes intact 10 molecules as well as fragments thereof, such as Fab and F(ab')₂ fragments, and chimeric, human and humanized antibodies, which are functionally capable of binding an epitopic determinant of the peptides.

15 A preferred method for the identification and isolation of antibody binding domains which exhibit binding with the peptides is the bacteriophage 1 vector system. This vector system has been used to express a combinatorial library of Fab fragments from the mouse antibody repertoire in 20 *Escherichia coli*, see Huse et al., *Science* 246: 1275-81 (1989), and from the human antibody repertoire. Mullinax et al., *Proc. Nat'l Acad. Sci. USA* 87: 8095-99 (1990).

25 For purposes of the invention, an antibody or nucleic acid probe specific for the peptide may be used to detect the presence of the peptide (in the case of an antibody probe) or nucleotide (in the case of the nucleic acid probe) in biological fluids or tissues suspected of containing the

-62-

peptide. Oligonucleotide primers based on any coding sequence region in the peptide sequence are useful for amplifying DNA or RNA, for example by PCR. Any specimen containing a detectable amount of antigen can be used. A 5 preferred sample of this invention is tissue taken from the lung. Alternatively, biological fluids which may contain cells of the lung may be used.

The term "subject" as used herein includes but is not limited 10 to mammals. In a preferred embodiment, the subject is a human being.

Another technique which may also result in greater sensitivity consists of coupling the probe to low molecular 15 weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenol, pyridoxal, and fluorescein, which can react with specific antihapten antibodies.

20

The monoclonal antibodies of the invention are suitable for use in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the monoclonal antibodies in these immunoassays can be detectably 25 labeled in various ways. Examples of types of immunoassays which can utilize monoclonal antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are

-63-

the radioimmunoassay (RIA) and the sandwich (immuno-metric) assay. Detection of the antigens using the monoclonal antibodies of the invention can be performed utilizing immunoassays which are run in either the forward, reverse, or 5 simultaneous modes, including immunohistochemical assays on physiological samples. Alternatively, the antibody of the invention can be used to detect peptides present in electrophoretically dispersed gel protocols such as Western blots and two-dimensional gels.

10

The monoclonal antibodies of the invention can be bound to many different carriers and used to detect the presence of a peptide of the invention. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, 15 dextran, nylon, amylases, natural and modified celluloses, poly-acryl-amides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention.

20 In performing the assays it may be desirable to include certain "blockers" in the incubation medium (usually added with the labeled soluble antibody). The "blockers" are added to assure that non-specific proteins, proteases, or anti-heterophilic immunoglobulins to anti-peptide 25 immunoglobulins present in the experimental sample do not cross-link or destroy the antibodies on the solid phase support, or the radiolabeled indicator anti-body, to yield false positive or false negative results. The selection of

-64-

"blockers" therefore may add substantially to the specificity of the assays described in the present invention.

It has been found that a number of nonrelevant (i.e.,
5 nonspecific) antibodies of the same class or subclass (isotype) as those used in the assays (e.g., IgG1, IgG2a, IgM, etc.) can be used as "blockers." The "blockers" are used at a level high enough to maintain the proper sensitivity yet inhibit any unwanted interference by mutually
10 occurring cross reactive proteins in the specimen (normally 1-100 mg/ml).

In this description, the term "epitope" denotes any determinant capable of specific interaction with the
15 monoclonal antibodies of the invention. Epitopic determinants usually comprise chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

20

In using the monoclonal antibodies of the invention for the in vivo detection of antigen, the detectably labeled monoclonal antibody is given in a dose which is diagnostically effective. The term "diagnostically
25 effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the antigen for which the monoclonal antibody is specific. The dosage of detectably

-65-

labeled mono-clonal antibody for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. The dosage of monoclonal antibody can vary from about 0.001 mg/m², to about 500 mg/m², preferably 5 0.1 mg/m² to about 200 mg/m², most preferably about 0.1 mg/m² to about 10 mg/m². Such dosages may vary, for example, depending on whether multiple injections are given and other factors.

10 For in vivo diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope 15 for in vivo diagnosis is that the half-life of the radioisotope be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for in vivo imaging 20 will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may be readily detected by conventional gamma cameras.

For in vivo diagnosis, radioisotopes may be bound to 25 immunoglobulin either directly or indirectly by using an intermediate functional group. Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional

-66-

chelating agents such as diethylene-triamine-pentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal anti-bodies of the invention are
5 111In, 97Ru, 67Ga, 68Ga, 72As, 89Zr, and 201Tl.

The monoclonal antibodies of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron
10 spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized.

Usually gamma and positron emitting radioisotopes are used for camera imaging and para-magnetic isotopes for MRI. Elements which are particularly useful in such techniques
15 include 157Gd, 55Mn, 162Dy, 52Cr, and 56Fe.

The monoclonal antibodies of the invention can be used to monitor the course of amelioration of pulmonary hypertension. Thus, by measuring the increase or decrease in the number of
20 cells expressing a peptide or changes in peptide present in various body fluids, such as samples of lung tissue or material wiped or swabbed from lung tissue, it would be possible to determine whether a particular therapeutic regimen aimed at ameliorating the disorder is effective.

25

The monoclonal antibodies of the invention can also be used, alone or in combination with effector cells, see Douillard et

-67-

al., Hybridoma 5 (Supp. 1): S139 (1986), for treatment of pulmonary hypertension in a subject.

When used for immunotherapy, the monoclonal antibodies of the
5 invention may be unlabeled or attached to a therapeutic agent. These agents can be coupled either directly or indirectly to the monoclonal antibodies of the invention. One example of indirect coupling is by use of a spacer moiety. These spacer moieties, in turn, can be either
10 insoluble or soluble, see Diener et al., Science 231: 148 (1986), and can be selected to enable drug release from the monoclonal antibody molecule at the target site. Examples of therapeutic agents which can be coupled to the monoclonal antibodies of the invention for immunotherapy are drugs,
15 radioisotopes, lectins, and toxins.

The drugs which can be conjugated to the monoclonal antibodies of the invention include non-proteinaceous as well as proteinaceous drugs. The terms "non-proteinaceous drugs"
20 encompasses compounds which are classically referred to as drugs, for example, mitomycin C, daunorubicin, vinblastine, and others used to treat cancer.

The proteinaceous drugs with which the monoclonal antibodies
25 of the invention can be joined include immunomodulators and other biological response modifiers. The term "biological response modifiers" encompasses substances which are involved in modifying the biological response in such manner as to

-68-

ameliorate or eliminate pulmonary hypertension. Examples of immune response modifiers include such compounds as flolan, beraprost, and uniprost.

5 It is also possible to utilize liposomes with the monoclonal antibodies of the invention in their membrane to specifically deliver the liposome to the tissue expressing the mutant peptide. These liposomes can be produced such that they contain, in addition to the monoclonal antibody, such
10 immunotherapeutic agents as those described above which would then be released at the tumor site. Wolff et al., Biochemical et Biophysical Acta 802: 259 (1984).

The dosage ranges for the administration of monoclonal
15 antibodies of the invention are those large enough to produce the desired effect in which the symptoms of the disease are ameliorated. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage
20 will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any complication. Dosage can vary from about 0.1 mg/kg to about 2000 mg/kg, preferably about
25 0.1 mg/kg to about 500 mg/kg, in one or more dose administrations daily, for one or several days. Generally, when the monoclonal antibodies of the invention are administered conjugated with therapeutic agents, lower

-69-

dosages, comparable to those used for in vivo diagnostic imaging, can be used.

The monoclonal antibodies of the invention can be
5 administered parenterally by injection or by gradual perfusion over time. The monoclonal antibodies of the invention can be administered intravenously, intra-peritoneally, intramuscularly, subcutaneously, intra-cavity, or transdermally, alone or in combination with
10 effector cells.

The present invention also provides a method for treating a subject with pulmonary hypertension using a nucleotide sequence encoding the non-mutant peptide.

15

Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs,
20 it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it. Cech, J. Amer. Med. Assn. 260: 3030 (1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.

25

There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and

-70-

"hammerhead"-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while "hammerhead"-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the 5 greater the likelihood that sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.

10

The present invention also provides gene therapy for the treatment of pulmonary hypertension mediated by the mutant sequences described herein. Such therapy requires introduction of the appropriate, normal nucleotide sequence 15 (antisense or encoding strand) into cells of subjects having the proliferative disorder. Such therapy may utilize ex vivo transformation of cells followed by their re-introduction into a subject or direct administration of the normal peptide or nucleotide sequence encoding it. Various viral vectors 20 which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single 25 foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). A number of additional retroviral vectors can incorporate multiple genes. All of these vectors

-71-

can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a sequence of interest into the viral vector along with another gene which encodes the ligand for a receptor on 5 a specific target cell, for example, the vector is rendered target specific. Retroviral vectors can be made target specific by inserting, for example, a polynucleotide encoding a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral 10 vector.

Since recombinant retroviruses are defective in one or more genes, they require assistance in order to produce infectious vector particles. Helper cell lines which have deletions of 15 the packaging signal include but are not limited to Y2, PA317 and PA12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other 20 genes of interest, the vector can be packaged and vector virion produced.

Alternatively, NIH 3T3 or other tissue culture cells can be directly transfected with plasmids encoding the retroviral 25 structural genes gag, pol and env by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the

- 72 -

culture medium.

Other targeted delivery systems for nucleotides include macromolecule complexes, nanocapsules, microspheres, beads,
5 and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (ULV), which range in size from 0.2-4.0
10 μm can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form. Fraley et al., Trends Biochem. Sci. 6: 77 (1981).

15

The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids
20 may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include
25 phosphatidyl compounds, such as phosphati-dyl-glycerol, phosphatidylcholine, phosphatidyserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are

-73-

diacyl-phosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoyl-phosphatidylcholine and 5 distearoylphosphatidylcholine.

The targeting of liposomes has been classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for 10 example, organ-specific, cell-specific and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system 15 (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order 20 to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a hyposomal targeted 25 delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the

-74-

lipid chains to the targeting ligand.

In general, the compounds bound to the surface of the targeted delivery system will be ligands and receptors which
5 will allow the targeted delivery system to find and "home in" on the desired cells. A ligand may be any compound of interest which will bind to another compound, such as a receptor.

10 In general, surface membrane proteins which bind to specific effector molecules are referred to as receptors. In the present invention, antibodies of the invention are preferred receptors. Antibodies can be used to target liposomes to specific cell-surface ligands, in this case the peptides of
15 choice. Preferably, the target tissue is lung tissue. A number of procedures can be used to covalently attach either polyclonal or monoclonal antibodies to a liposome bilayer. Antibody-targeted liposomes can include mono-clonal or polygonal antibodies or fragments thereof such as Fab, or
20 F(ab')₂, as long as they bind efficiently to an the antigenic epitope on the target cells.

Preparations for parenteral administration include sterile aqueous or nonaqueous solutions, suspensions, and emulsions.
25 Examples of non aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions,

-75-

emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents and inert gases and the like.

10

The invention also relates to a method for preparing a medicament or pharmaceutical composition comprising the wildtype BMPR2 polypeptide of the invention, the medicament being used for therapy of pulmonary hypertension.

15

This invention will be better understood from the Experimental Details that follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as 20 described more fully in the claims that follow thereafter.

-76-

Experimental Details

Familial Primary Pulmonary Hypertension is a rare autosomal dominant disorder with reduced penetrance that has been mapped to a 3-centimorgan region on chromosome 2q34 (*PPH1* locus). The phenotype is characterized by monoclonal plexiform lesions of proliferating endothelial cells in pulmonary arterioles that lead to elevated pulmonary artery pressures, right ventricular failure, and death. Although PPH is rare, cases secondary to known etiologies are more common and include those associated with the appetite suppressant drugs, including phentermine-fenfluramine. We genotyped 35 multiplex families with the disorder using 27 microsatellite markers, constructed disease haplotypes, and looked for evidence of haplotype sharing across families using the program TRANSMIT. Suggestive evidence of sharing was observed using markers GGAA19e07 and D2S307, and three nearby candidate genes were examined by dHPLC using individuals from 19 families. One of these genes (*BMPR2*), which encodes the bone morphogenetic protein receptor-II (BMPR-II), was found to contain 5 mutations that predict premature termination of the protein product and 2 missense mutations. These mutations were not observed in 196 control chromosomes. These findings indicate that the BMP signaling pathway is defective in patients with PPH and may implicate the pathway in the non-familial forms of the disease.

We have collected a number of multiplex families with PPH

-77-

using experimental protocols approved by the Institutional Review Board of Columbia University College of Physicians and Surgeons. Methods used for clinical examination, as well as the diagnostic criteria, have been described elsewhere (Morse et al. 1997). Using DNA that was extracted from whole-blood samples or formalin-fixed, paraffin-embedded tissue we genotyped 35 of these families (72 affected and 319 normals and carriers) using 27 microsatellite markers located in the 3-centimorgan minimal genetic region as previously described (Deng et al. 2000). Using the genetic model and marker order determined by radiation hybrid mapping (Deng et al. 2000), a 10-marker multipoint analysis using GENEHUNTER 2.0 (Kruglyak et al. 1996), gave a nearly constant lod score of 10 across the region (data not shown). The maximum lod scores of the 15 2-point analyses, using MLINK from FASTLINK v4.1p (Cottingham, Jr., Idury, and Schaffer 1993), at a recombination fraction of zero were more variable, ranging from 0.6 to 8.6, with the higher scores clustering towards the telomeric end (data not shown). Given the low prevalence 20 of the disorder and that some of the families were from a common founder, we re-constructed the 27-marker microsatellite disease haplotype from each when possible and visually inspected them for shared segments. No obvious 25 shared DNA segments were found, so we used the haplotype analysis program, TRANSMIT v2.5 1999 (Clayton 1999), to look in a more rigorous fashion. Suggestive evidence of sharing ($p=0.07$) was found with the 345/214 base pair haplotype of markers GGAA19e07 and D2S307. Since these markers were in the telomeric cluster we began our mutation scan in this 30 region.

-78-

We investigated the genetic variation in the coding sequence of three nearby candidate genes by examining in 22 individuals from the 19 FPPH families and 2 normal controls using dHPLC with a WAVE® Nucleic Acid Fragment Analysis System from Transgenomics, Inc. (Omaha, NE), as per the manufacturers directions and as described (Underhill et al. 1997; O'Donovan et al. 1998). These individuals were chosen on the basis of the amount of DNA available. PCR amplification products (max size=602 bp) were run with up to 10 three melting profiles for fragments with multiple melting domains. DNA sequence determination of fragments containing potential variants were performed by cycle sequencing using Big Dye™ terminators from Applied BioSystems Inc., (Foster City, CA) and sequencing products were resolved on Long Ranger™ gels (BioWhittaker Molecular Applications, Rockland, ME) and detected with an ABI Model 377 DNA sequencer (ABI, Foster City, CA). DNA sequence traces were analyzed using Vector NTI suite 5.5 (Informatix Inc., Bethesda, MD). The first two genes, *CD28* and *CTLA4*, were candidates due to their 20 involvement in immune system regulation (Morse and Barst 1994). No variation in *CD28* was observed. In *CTLA4*, we found one previously unreported SNP (49A>G) with an allele frequency of 0.50 that causes a non-conservative change in protein structure (A17T). It was homozygous in some of the 25 patients and one of the controls and was ruled out as a potential disease mutation.

The third positional candidate, the gene encoding the bone morphogenetic protein receptor-II (*BMPR2*, also known as *T-*

-79-

ALK, *CL4-1* and *BRK-3*), a member of the TGF- β receptor superfamily, was suggested by the role of the BMP signaling pathway in lung morphogenesis (Warburton et al. 2000). The cDNA sequence of this approximately 4 kilobase gene encoding 5 a 1038 amino acid protein had been previously described (Kawabata, Chytil, and Moses 1995; Liu et al. 1995; Rosenzweig et al. 1995; Nohno et al. 1995). To deduce the genomic structure of *BMPR2* (fig. 1 and 2) we found homologous genomic sequences to exons 1, and 8-13 by querying the NCBI 10 high-throughput genome sequence (HTGS) database using BLAST (Altschul et al. 1990). The intron size and DNA sequence of the other intron-exon boundaries were determined by amplifying and sequencing PCR products using oligonucleotide primers designed to amplify across neighboring exons, or out 15 to a nearby *Alu* repeats, using the structure of mouse *BMPR2* (Beppu et al. 1997) as a guide. We then designed oligonucleotide primers to amplify the exons from genomic DNA of the patients. These PCR fragments were screened by dHPLC and the DNA sequence of those containing apparent variation 20 was determined. We observed mutations that are likely to disrupt the function of the receptor in 9 of the 19 families screened. Five of these predict premature termination of BMPR-II in exons 4, 6, 8 and 12, and each was only seen in one family (table 1 and fig. 2). In addition, a SNP in exon 25 11 that causes a non-conservative change in amino acid sequence, from an arginine, conserved in all known type II TGF- β superfamily receptors (fig. 3), to tryptophan was seen in three families (Table 1 and Fig. 2). The same arginine was changed to glutamine in another family (PPH019), but both 30 parents were genotypically normal. The observation of this

-80-

new mutation suggests that sporadic cases of PPH might also be caused by mutations in *BMPR2*. Except for this family, the expected pattern of mutations was observed when all additional members of the other 8 families were screened 5 using dHPLC and DNA sequencing. None of the putative mutations were observed in 96 additional samples (196 chromosomes total). Applying Fisher's exact test to the data for all nine mutations, we observed a significant difference (p-value <0.0001) in mutation rate between cases and 10 controls. We also observed a synonymous SNP (2811G>A) with a minor allele frequency of 21% in both samples.

The mutation in exon 4 is in the transmembrane domain and those in exons 6, 8 and 11 are in the kinase domain of this 15 serine/threonine kinase receptor (figure 2). By analogy to studies of the TbR-II gene product (Wieser et al. 1993), at least three of these mutations (exons 4, 6 and 8) should encode a non-functional receptor that is unable to phosphorylate a type-I receptor and propagate the signal from 20 a BMP ligand. The two mutations in exon 11 change Arg491. Since it is highly conserved and arginine is the most frequently changed amino acid in disease mutations (Human Gene Mutation Database), Arg491 is probably important to the function of BMPR-II. The mutations in exon 12 occur in the 25 intracellular C-terminal domain of unknown function that is unique to BMPR-II.

We screened the entire publicly available coding sequence of

-81-

BMPR2, but failed to find a causative mutation in 10 of the 19 families. The microsatellite data are consistent, but not conclusive, with linkage to *PPH1* in all 19, but it is possible that the families with little linkage information 5 could be unlinked to 2q34 and may have mutations in other genes in the BMP signaling pathway. However, several of the linked families are large (individual lod scores >2), suggesting that we have not screened the entire gene. mRNA transcripts of 5, 6.5, 8 and 11.5 kb have been observed on 10 Northern blots, with the longest transcript predominating in lung (Kawabata, Chytil, and Moses 1995; Rosenzweig et al. 1995; Nohno et al. 1995), so we may have missed some alternatively spliced exons in our screen. In addition, there is a (GGC)₁₂ trinucleotide repeat at the 5' end of the 15 gene, at positions -928 to -963. This repeat is polymorphic in our families. Using PCR, we have not observed evidence of expansion of the repeat that would be consistent with the suggestion of anticipation in PPH (Loyd et al. 1995), but detection of this event might require a Southern blot and we 20 have a limited quantity of DNA from the affected individuals (deceased) in many of our families.

So how do these mutations cause PPH? It is unlikely that they act as a dominant-negative by inhibiting apoptotic effect of the TGF- β pathway because BMPR-II does not 25 associate with type-I receptors of the TGF- β family in transient expression assays using mammalian cells (Liu et al. 1995), even though this occurs *in vitro* (Kawabata, Chytil, and Moses 1995; Liu et al. 1995; Nohno et al. 1995). As would be predicted from what is known about the role of the

-82-

BMP signaling pathway in early development, mice homozygous for a mutation in the kinase domain of *BMPR2* die at day 9.5, prior to gastrulation (heterozygotes are grossly normal) (Beppu et al. 2000), so this function of the pathway must be functioning in patients with PPH. The BMP pathway induces apoptosis in some cell types (Soda et al. 1998; Kimura et al. 2000), so a partial block of signal transmission by haplo-insufficiency of BMPR-II might have a slow proliferative effect. BMP signaling may occur through both the Smad (Massague 1998) and mitogen-activated protein kinase (MAPK) (Kimura et al. 2000) cascades and both are inhibited by Smad6, which can be induced by vascular shear stress (Topper et al. 1997). The reduced apoptotic signals from the BMP pathway, caused by either mutations in *BMPR2*, other molecules in the signaling cascades (by analogy to hereditary hemorrhagic telangiectasia (Massague 1998)), or shear stress via Smad6, possibly after an initial nidus of vascular injury, might underlie many forms of PPH, including those associated with HIV or appetite suppressant drugs.

- 83 -

References

1. Abenham L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. *N Engl J Med* 335 (9):609-616
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. *J Mol Biol* 215 (3):403-410
3. Barst RJ, Rubin LJ, Long WA, McGoan MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med* 334 (5):296-302
4. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K (2000) BMP type II receptor is required for gastrulation and early development of mouse embryos. *Dev Biol* 221 (1):249-258
5. Beppu H, Minowa O, Miyazono K, Kawabata M (1997) cDNA cloning and genomic organization of the mouse BMP type II receptor. *Biochem Biophys Res Commun* 235 (3):499-504

-84-

6. Clayton D (1999) A Generalization of the Transmission/Disequilibrium Test for Uncertain-Haplotype Transmission. *Am J Hum Genet* 65 (4):1170-1177
- 5 7. Cottingham RW, Jr., Idury RM, Schaffer AA (1993) Faster sequential genetic linkage computations. *Am J Hum Genet* 53:252-263
8. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 115 (5):343-349
- 15 9. Deng Z, Haghghi F, Helleby L, Vanterpool K, Horn EM, Barst RJ, Hodge SE, Morse JH, Knowles JA (2000) Fine mapping of *PPH1*, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. *Am J Respir Crit Care Med* 161 (3 Pt 1):1055-1059
- 20 10. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT (1981) Pulmonary hypertension and fenfluramine. *Br Med J (Clin Res Ed)* 283 (6296):881-883
- 25 11. Kawabata M, Chytil A, Moses HL (1995) Cloning of a novel type II serine/threonine kinase receptor through

-85-

interaction with the type I transforming growth factor-beta receptor. *J Biol Chem* 270 (10):5625-5630

12. Kimura N, Matsuo R, Shibuya H, Nakashima K, Taga T
5 (2000) BMP2-induced Apoptosis Is Mediated by Activation
of the TAK1-p38 Kinase Pathway That Is Negatively
Regulated by Smad6. *J Biol Chem* 275 (23):17647-17652
13. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES (1996)
10 Parametric and nonparametric linkage analysis: a unified
multipoint approach. *Am J Hum Genet* 58 (6):1347-1363
14. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF,
Tuder RM (1998) Monoclonal endothelial cell
15 proliferation is present in primary but not secondary
pulmonary hypertension. *J Clin Invest* 101 (5):927-934
15. Liu F, Ventura F, Doody J, Massague J (1995) Human type
II receptor for bone morphogenic proteins (BMPs):
20 extension of the two-kinase receptor model to the BMPs.
Mol Cell Biol 15 (7):3479-3486
16. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips
JA, Newman JH (1995) Genetic anticipation and abnormal
25 gender ratio at birth in familial primary pulmonary
hypertension. *Am J Respir Crit Care Med* 152 (1):93-97

-86-

17. Massague J (1998) TGF-beta signal transduction. *Annu Rev Biochem* 67:753-791
18. Morse JH and Barst RJ (1994) Immunological disturbances
5 in primary pulmonary hypertension. *Sem Resp Crit Care*
15:222-229
19. Morse J. H., Jones, A., DiBenedetto, A., Hodge, S. E.,
and Nygaard, T. G. (1996) Genetic mapping of primary
10 pulmonary hypertension: Evidence for linkage to
chromosome 2 in a large family. *Circulation* 94 (8):I-46
20. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC,
Nygaard TG (1997) Mapping of familial primary pulmonary
15 hypertension locus (PPH1) to chromosome 2q31-q32.
Circulation 95 (12):2603-2606
21. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH,
Arnold ND, Siemieniak DR, Wheeler L, Phillips JA, Newman
20 JH, Conneally PM, Ginsburg D, Loyd JE (1997)
Localization of the gene for familial primary pulmonary
hypertension to chromosome 2q31-32. *Nat Genet* 15
(3):277-280
- 25
22. Nohno T, Ishikawa T, Saito T, Hosokawa K, Noji S,

-87-

- Wolsing DH, Rosenbaum JS (1995) Identification of a
human type II receptor for bone morphogenetic protein-4
that forms differential heteromeric complexes with bone
morphogenetic protein type I receptors. *J Biol Chem* 270
5 (38):22522-22526
23. O'Donovan MC, Oefner PJ, Roberts SC, Austin J,
Hoogendoorn B, Guy C, Speight G, Upadhyaya M, Sommer SS,
McGuffin P (1998) Blind Analysis of Denaturing High-
10 Performance Liquid Chromatography as a Tool for Mutation
Detection. *Genomics* 52 (1):44-49
24. Pasque MK, Trulock EP, Cooper JD, Triantafillou AN,
Huddleston CB, Rosenbloom M, Sundaresan S, Cox JL,
15 Patterson GA (1995) Single lung transplantation for
pulmonary hypertension. Single institution experience in
34 patients. *Circulation* 92 (8):2252-2258
- 20 25. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage
BH, Detre KM, Fishman AP, Goldring RM, Groves BM,
Koerner SK (1987) Primary pulmonary hypertension. A
national prospective study. *Ann Intern Med* 107 (2):216-
223
- 25 26. Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita
H, ten Dijke P, Heldin CH, Miyazono K (1995) Cloning and
characterization of a human type II receptor for bone

-88-

morphogenetic proteins. Proc Natl Acad Sci U S A 92 (17) :7632-7636

27. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez
5 L, Timony GA, Von Hoff DD, Izbicka E (1998) Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9 (4) :327-331
- 10 28. Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, Feeley R, Gimeno CJ, Woolf EA, Tayber O, Mays GG, Sampson BA, Schoen FJ, Gimbrone MA, Jr., Falb D (1997) Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A 94 (17) :9314-9319
15
- 20 29. Underhill PA, Jin L, Lin AA, Mehdi SQ, Jenkins T, Vollrath D, Davis RW, Cavalli-Sforza LL, Oefner PJ (1997) Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 7 (10) :996-1005
30. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV (2000) The molecular basis of lung morphogenesis. Mech Dev 92 (1) :55-81
25

-89-

31. Wieser R, Attisano L, Wrana JL, Massague J (1993)
.. Signaling activity of transforming growth factor beta
type II receptors lacking specific domains in the
cytoplasmic region. Mol Cell Biol 13 (12):7239-7247

5

32. Galloway, S.M., McNatty, K.P., Cambridge, L.M.,
Laitinen, M.P., Juengel, J.L., Jokiranta, T.S.,
McLaren, R.J., Luiro, K., Dodds, K.G., Montgomery, G.W.,

10 Beattie, A.E., Davis, G.H., and Ritvos, O. (2000).
Mutations in an oocyte-derived growth factor gene
(BMP15) cause increased ovulation rate and infertility
in a dosage-sensitive manner [In Process Citation]. Nat.
Genet. 25, 279-283.

15 33. Morse, J.H. and Barst, R.J. (1997). Detection of familial
primary pulmonary hypertension by genetic testing
[letter]. N. Engl. J. Med. 337, 202-203.

-90-

What is claimed:

1. A method of detecting whether a subject is either predisposed to or afflicted with a pulmonary disease which comprises (1) obtaining a suitable sample from the subject; and (2) detecting in the sample a bone morphogenetic protein receptor-II mutation which is not present in wildtype bone morphogenetic protein receptor-II, wherein the presence of a mutation indicates that the subject is predisposed to or afflicted with the pulmonary disease.
2. The method of claim 1, wherein the suitable sample is a nucleic acid sample, and the mutation is detected in a nucleic acid encoding bone morphogenetic protein receptor-II.
3. The method of claim 1, wherein the suitable sample is one which comprises a bone morphogenetic protein receptor-II polypeptide, and the mutation is detected in the bone morphogenetic protein receptor-II polypeptide.
4. The method of claim 1, wherein the pulmonary disease is Primary Pulmonary Hypertension.
- 25 5. The method of claim 4, wherein the Primary Pulmonary Hypertension is Familial Primary Pulmonary Hypertension.

-91-

6. The method of claim 1, wherein a bone morphogenetic protein receptor-II polypeptide is encoded by a gene which is located on chromosome 2q34.

5 7. The method of claim 1, wherein a wildtype nucleic acid encoding a bone morphogenetic protein receptor-II polypeptide comprises consecutive nucleotides comprising the nucleic acid sequence set forth in SEQ ID NO: 1.

10

8. The method of claim 1, wherein a wildtype bone morphogenetic protein receptor-II polypeptide comprises consecutive amino acids comprising the amino acid sequence set forth in SEQ ID NO: 2.

15

9. The method of claim 1, wherein the mutation results in a truncated bone morphogenetic protein receptor-II.

20

10. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a nucleotide segment guanosine-guanosine-guanosine-guanosine-adenosine located at positions 1099-1103 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

25

11. The method of claim 3, wherein the mutated bone

-92-

morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a glutamic acid residue located at position 368 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.

5
12. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a thymidine residue located at position 2579 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in Seq ID NO:1.

10
13. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at an asparagine residue located at position 861 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.

15
20 14. The method of claim 2, wherein the mutated nucleic acid comprises a replacement of a nucleotide segment cytosine-thymidine-thymidine-thymidine located at positions 507-510 in a wildtype nucleic acid with a nucleotide segment adenosine-adenosine-adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

25
15. The method of claim 3, wherein the mutated bone

-93-

morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position 169 in a wildtype polypeptide to a termination codon, which wildtype polypeptide comprises the sequence set forth in
5 SEQ ID NO:2.

16. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a cytosine located at position number 2617 in a wildtype nucleic acid to a thymidine,
10 which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
17. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position 873 in a wiltype polypeptide to a termination codon, which wildtype polypeptide comprises the sequence set forth in
15 SEQ ID NO:2.
- 20 18. The method of claim 2, wherein the mutated nucleic acid comprises a replacement of a nucleotide segment adenosine-guanosine present at positions 690-691 in a wildtype nucleic acid with a thymidine residue, which wildtype nucleic acid comprises the sequence set forth
25 in SEQ ID NO:1.
19. The method of claim 3, wherein the mutated bone

- 94 -

morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a lysine residue located at position 230 in a wildtype polypeptide, which wildtype polypeptide comprises the sequence set forth in SEQ ID
5 NO:2.

20. The method of claim 2, wherein the mutation is a missense mutation.

10 21. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a cytosine located at position number 1471 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

15

22. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position 491 in a wildtype polypeptide to a tryptophan, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
20

25 23. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a guanosine located at position number 1472 in a wildtype nucleic acid to an adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

-95-

24. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position number 491 in a wildtype polypeptide to a glutamine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
- 5
25. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a nucleotide segment adenosine-thymidine-thymidine-thymidine located at positions 1248-1251 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
- 10
26. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an phenylalanine located at position number 417 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
- 15
- 20 27. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a cytosine located at position number 994 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
- 25
28. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises

-96-

a mutation of an arginine located at position number 332 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

5

29. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a thymidine located at position number 295 in a wildtype nucleic acid to a cytosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
10
30. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 99 in a wildtype polypeptide to an arginine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
15
31. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a guanosine residue located at position 1097 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in Seq ID NO:1.
20
32. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a proline residue located at position 366 in the wildtype polypeptide, which wildtype
25

-97-

polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.

33. The method of claim 2, wherein the mutated nucleic acid
5 comprises a mutation of a guanosine located at position number 727 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

10 34. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a glutamic acid located at position number 243 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ
15 ID NO:2.

20 35. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of an adenine residue located at position 1214 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in Seq ID NO:1.

25 36. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at an aspartic acid residue located at position 405 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid

-98-

sequence set forth in SEQ ID NO:2.

37. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a nucleotide segment adenosine-cytosine located at positions 2441-2442 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
5
38. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a frameshift mutation at a histidine residue located at position 814 in the wildtype polypeptide, which wildtype polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2.
10
39. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a cytosine located at position number 2695 in a wildtype nucleic acid to a thymidine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
15
20
40. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of an arginine located at position number 899 in a wildtype polypeptide to a stop codon, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
25

-99-

41. The method of claim 2, wherein the mutated nucleic acid comprises a deletion of a nucleotide segment present at positions 189-209 in a wildtype nucleic acid, which wildtype nucleic acid comprises the sequence set forth
5 in SEQ ID NO:1.

42. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a deletion of an amino acid segment serine-threonine-cysteine-tyrosine-glycine-leucine-tryptophan located at
10 position numbers 64-70 in a wildtype polypeptide, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.

15 43. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a guanosine located at position number 296 in a wildtype nucleic acid to a adenosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

20 44. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 99 in a wildtype polypeptide to a tyrosine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
25

45. The method of claim 2, wherein the mutated nucleic acid

-100-

comprises a mutation of a thymidine located at position number 250 in a wildtype nucleic acid to a cytosine, which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.

5

46. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 84 in a wildtype polypeptide to an arginine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
10
47. The method of claim 2, wherein the mutated nucleic acid comprises a mutation of a guanosine located at position number 1040 in a wildtype nucleic acid to a adenosine,
15 which wildtype nucleic acid comprises the sequence set forth in SEQ ID NO:1.
48. The method of claim 3, wherein the mutated bone morphogenetic protein receptor-II polypeptide comprises a mutation of a cysteine located at position number 347 in a wildtype polypeptide to a tyrosine, which wildtype polypeptide has the sequence set forth in SEQ ID NO:2.
20
49. The method of claim 5, wherein the subject is suffering from an asthmatic symptom, so as to thereby prevent a
25 subject afflicted with Familial Primary Pulmonary Hypertension from being misdiagnosed as asthmatic.

-101-

50. The method of claim 49, wherein the asthmatic symptom is wheezing or intermittent shortness of breath.

51. A method of predicting an increased likelihood of a
5 subject giving birth to twins or triplets which comprises:

- a) obtaining a suitable nucleic acid sample from the subject;
- b) detecting the presence of one copy of a mutant
10 nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide, thereby indicating that the subject is heterozygous for the mutation, wherein heterozygosity predicts an increased likelihood of the subject giving birth to twins or triplets.

15

52. A method of predicting an increased likelihood of a subject having a miscarriage prior to giving birth to a child which comprises:

- a) obtaining a suitable nucleic acid sample from the subject;
- b) detecting the presence of two copies of a mutant nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide, thereby indicating that the subject is homozygous for the mutation,
20 wherein homozygosity predicts an increased likelihood of the subject having a miscarriage prior to giving

-102-

birth to a child.

53. A method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises
5 introducing a nucleic acid encoding a wildtype bone morphogenetic protein receptor-II polypeptide operably linked to a promotor into a suitable cell under conditions such that the nucleic acid expresses the wildtype bone morphogenetic protein receptor-II protein
10 so as to thereby prevent and/or treat Familial Primary Pulmonary Hypertension in the subject.
54. The method of claim 53, wherein the suitable cell is a lung cell.
15
55. A method of preventing and/or treating Familial Primary Pulmonary Hypertension in a subject which comprises administering to the subject an effective amount of a wildtype bone morphogenetic protein receptor-II polypeptide comprising consecutive amino acids having the sequence set forth in SEQ ID NO:2 to prevent and/or treat Familial Primary Pulmonary Hypertension in the subject.
20
- 25 56. A method of detecting whether a subject is either predisposed to or afflicted with Familial Primary Pulmonary Hypertension which comprises:

-103-

- a) obtaining a suitable nucleic acid sample from the subject; and
- b) detecting the presence of a (GGC)₁₂ trinucleotide repeat at positions -928 to -963 in the 5' end of the bone morphogenetic protein receptor-II gene,
5 wherein the presence of the trinucleotide repeat indicates that the subject is either predisposed to or afflicted with Familial Primary Pulmonary Hypertension.

10 57. A method of screening for a compound capable of treating Familial Primary Pulmonary Hypertension which comprises:

- a) contacting a cell which expresses a mutant bone morphogenetic protein receptor-II with the compound; and
- b) determining whether the compound is capable of reversing the functional deficit present in
15 Familial Primary Pulmonary Hypertension in the cell,

wherein a reversal of the functional deficit in the cell
20 indicates that the compound is capable of treating Familial Primary Pulmonary Hypertension.

25 58. The method of claim 57, wherein the functional deficit is reduced kinase activity for the bone morphogenetic protein receptor-II.

-104-

59. A method of obtaining a composition which comprises:

- a) identifying a compound capable of treating Familial Primary Pulmonary Hypertension by the method of claim 57; and
- 5 b) admixing the compound so identified or a homolog or derivative thereof with a carrier.

60. A transgenic non-human animal whose cells comprise a mutant nucleic acid which encodes a bone morphogenetic protein receptor-II polypeptide.

10

61. The transgenic non-human animal of claim 60, wherein the non-human animal exhibits primary pulmonary hypertension.

15 62. The transgenic non-human animal of claim 60, wherein the nucleic acid is operatively linked to a promotor.

20 63. The transgenic non-human animal of claim 60, wherein the non-human animal is a mouse, a rat, a sheep, a dog, a primate or a reptile.

25

1/9

Figure 1-1

EXON (SIZE)	EXON 3'	INTRON (SIZE)	EXON 5'
EXON 1 (>460 bp)	GCT G Ala A	gtgaggtagctccggc.. gcaaggtagatactttc..	intron 1 (>30 kb) ..tttcctttattttag
EXON 2 (171 bp)	CAA G Gln G	gtaagtaaaagtaacc..	intron 2 (~2.3 kb) ..catattgtatattatag
EXON 3 (171 bp)	CTC A Leu S	gtaaaatttaccatt..	intron 3 (>30 kb) ..tttggtttttttttag
EXON 4 (111 bp)	ACA G Thr G	gtaaaatttaccatt..	intron 4 (~3.8 kb) ..ttccctgtttttatag
EXON 5 (92 bp)	TTC GAG Leu Glu	gtaaaggtttgcgtta.. gtaaaggttttcatatag..	intron 5 (~6 kb) ..ttaaaaacacttgcag
EXON 6 (231 bp)	CCC AAT Pro Asn	gtaaaggatgtcaata..	intron 6 (~4.1 kb) ..ttttccctttatatag
EXON 7 (115 bp)	GGA G Gly A	gtgagggtgtataaaaa..	intron 7 (>7 kb) ..aaatttatccaaacag
EXON 8 (161 bp)	AGC GAG Ser Glu	gtgaggtagtataaaaa..	intron 8 (~1.6 kb) ..actctaattttatcg
EXON 9 (148 bp)	CCA G Pro G	gtaaaaactactgtc..	intron 9 (>9.7 kb) ..tctacaaatccacag
EXON 10 (137 bp)	AGC CTG Ser Leu	gtaaaaaaaaactaa..	intron 10 (>5 kb) ..tactttgtttttacag
EXON 11 (173 bp)	GAA CG	gtaaaggaccctaagg..	intron 11 (>20 kb) ..cttttttttttttaag



2/9

Figure 1-2

g Asn
Glu Ar
Gtaaggaggatc..
intron 12 (~1.8 kb)
..cactttatttcag TA GGT
le Gly

Gln I

EXON 12 (1280 bp) CAG A
EXON 13 (>251 bp)

Figure 2**3/9**

4/9

Figure 3

491

R491W

BMPR-II [Homo sapiens]

BMPR-II [Mus musculus]

BMPR-II [Xenopus laevis]

BMPR-II [Gallus gallus]

TGFR-II [Homo sapiens]

TGFR-II [Mus musculus]

TGFR-II [Rattus Norvegicus]

ActR-II [Homo sapiens]

ActR-II [sheep]

ActR-II [Gallus gallus]

AMHR-II [Homo sapiens]

AMHR-II [Rattus norvegicus]

DAF4 [C. elegans]

XSTK3 [Xenopus laevis]

Consensus

LKETIEDCW DQD AEA W LTAQCAE ERMAEL
LKETIEDCW DQD AEA R LTAQCAE ERMAEL
LKETIEDCW DQD AEA R LTAQCAE ERMAEL
LKETIDDCW DQD AEA R LTAQCAE ERMAEL
LKETIEDCW DQD AEA R LTAQCAE ERMAEL
LKETIEDCW DQD AEA R LTAQCAE ERMAEL
VCE TLTECWDHDPEA R LTAQCV AER FSEL
VCE TLTECWDHDPEA R LTAQCV AER FSEL
VCE TLTECWDHDPEA R LTAQCV AER FSEL
LCVTIEDCW DHDAEA R LSAGC V E R V S LI
LCETIECWDHDAA R LSAGC V G E R I T Q M
LCETIECWDHDAA R LSAGC V E R I I Q M
LREILLED CWDADPEA R LTAECVQ Q Q R L A AL
LREILLED CWDADPEA R LTAECVQ Q Q R L A AL
LKKVTEEMW DPEAC A R ITAGCAFARVWNH
LCVTIEECWDHDAA R LSAGC V E R I S Q I
LKETIEDCWD DAEA R LTAQCV E R M A E L



5/9

Figure 4

Family #	#A/#C/#U	Exon #	DNA Sequence Variation	Protein Sequence Variation
PPH001, 008 and 021	4/5/13	11	1471C>T	R491W
PPH010	2/0/1	8	1099-1103delGGGGA	E368fsX1
PPH015	6/1/8	12	2579delT	N861fsX10
PPH017	3/0/6	4	507-510delCTTTinsAAA	C169X
PPH018	3/2/4	12	2617C>T	R873X
PPH019	1/0/5*	11	1472G>A	R491Q
PPH022	2/0/0	6	690-691delAGinsT	K230fsX21
PPH011		9	1248-1251delATT	F417X
PPH012		8	994C>T	R332X
PPH013		3	295T>C	C99R
PPH028		8	1097delG	P366fsX8
PPH032		6	727G>T	E243X
PPH037		9	1214delA	D405fsX6
PPH042		12	2441-2442delAC	H814fsX2
PPH047		12	2695C>T	R899X
M552		2	189-209del21	Del 64-70(STCYGLW)
PPH045		3	296G>A	C99Y
PPH052		3	250T>C	C84R
PPH67-6701		8	1040G>A	C347Y

Figure 5-1

6/9

+1 Met Thr Ser Ser Leu Gln Arg Pro Trp Arg Val Pro Trp Leu Pro Trp Thr

1 ATGACTTCCT CGCTGCAGCG GCCCTGGCGG GTGCCCTGGC TACCATGGAC

TACTGAAGGA GCGACGTCGC CGGGACCGCC CACGGGACCG ATGGTACCTG

+1 Thr Ile Leu Leu Val Ser Thr Ala Ala Ala Ser Gln Asn Gln Glu Arg Leu Cys

51 CATCCTGCTG GTCAGCACTG CGGCTGCTTC GCAGAATCAA GAACGGCTAT

GTAGGACGAC CAGTCGTGAC GCCGACGAAG CGTCTTAGTT CTTGCCGATA

+1 Cys Ala Phe Lys Asp Pro Ty Gln Gln Asp Leu Gly Ile Gly Glu Ser Arg

101 GTGCGTTAA AGATCCGTAT CAGCAAGACC TTGGGATAGG TGAGAGTACA

CACGCAAATT TCTAGGCATA GTCGTCTGG AACCTATCC ACTCTCATCT

+1 Ile Ser His Glu Asn Gly Thr Ile Leu Cys Ser Lys Gly Ser Thr Cys Tyr

151 ATCTCTCATG AAAATGGGAC AATATTATGC TCGAAAGGTA GCACCTGCTA

TAGAGAGTAC TTTTACCCCTG TTATAATACG AGCTTCCAT CGTGGACGAT

+1 Tyr Gly Leu Trp Glu Lys Ser Lys Gly Asp Ile Asn Leu Val Lys Gln Gly Cys

201 TGGCCTTGG GAGAAATCAA AAGGGACAT AAATCTTGTAA AACAAAGGAT

ACCGGAAACC CTCTTAGTT TTCCCCTGTA TTTAGAACAT TTTGTTCCATA

+1 Cys Trp Ser His Ile Gly Asp Pro Gln Glu Cys His Tyr Glu Glu Cys Val

251 GTTGGTCTCA CATTGGAGAT CCCCAAGAGT GTCACTATGA AGAATGTGTA

CAACCAGAGT GTAACCTCTA GGGGTTCTCA CAGTGATACT TCTTACACAT

+1 Val Thr Thr Pro Pro Ser Ile Gln Asn Gly Thr Tyr Arg Phe Cys Cys

301 GTAACTACCA CTCCCTCCCTC AATTAGAAT GGAACATACC GTTCTGCTG

CATTGATGGT GAGGAGGGAG TTAAGTCTTA CCTTGTATGG CAAAGACGAC

+1 Cys Cys Ser Thr Asp Leu Cys Asn Val Asn Phe Thr Glu Asn Phe Pro Pro Pro

351 TTGTAGCACA GATTATGTA ATGTCACATT TACTGAGAAT TTTCCACCTC

AACATCGTGT CTAAATACAT TACAGTTGAA ATGACTCTTA AAAGGTGGAG

+1 Pro Asp Thr Thr Pro Leu Ser Pro Pro His Ser Phe Asn Arg Asp Glu Thr

401 CTGACACAAAC ACCACTCAGT CCACCTCATT CATTAAACCG AGATGAGACA

GACTGTGTTG TGGTGAGTCA GGTGGAGTAA GTAAATTGGC TCTACTCTGT

+1 Ile Ile Ile Ala Leu Ala Ser Val Ser Val Leu Ala Val Ile Val Ala

451 ATAATCATTG CTTTGGCATE AGTCTCTGTA TTAGCTGTT TGATAGTTGC

TATTAGTAAC GAAACCGTAG TCAGAGACAT AATCGACAAA ACTATCAACG

+1 Ala Leu Cys Phe Gly Tyr Arg Met Leu Thr Gly Asp Arg Lys Gln Gly Leu His

501 CTTATGCTTT GGATACAGAA TGTTGACAGG AGACCGTAA CAAGGTCTTC

GAATACGAAA CCTATGTCCT ACAACTGTCC TCTGGCATTG GTTCCAGAAG

+1 His Ser Met Asn Met Met Glu Ala Ala Ala Ser Gln Pro Ser Leu Asp Leu

551 ACAGTATGAA CATGATGGAG GCAGCAGCAT CGAACCCCTC TCTTGATCTA

TGTCATACTT GTACTACCTC CGTCGTGTA GGCTTGGAG AGAACTAGAT

+1 Asp Asn Leu Lys Leu Leu Glu Leu Ile Gly Arg Gly Arg Tyr Gly Ala Val

601 GATAATCTGA AACTGTTGGA GCTGATTGGC CGAGGGTCGAT ATGGAGCAGT

CTATTAGACT TTGACAACCT CGACTAACCG GCTCCAGCTA TACCTCGTCA

+1 Val Tyr Lys Gly Ser Leu Asp Glu Arg Pro Val Ala Val Lys Val Phe Ser Phe

651 ATATAAAGGC TCCTTGGATG AGCGTCCAGT TGCTGTAAAA GTGTTTCCT

TATATTTCCG AGGAACCTAC TCGCAGGTCA ACGACATTGTT CACAAAGGAA

+1 Phe Ala Asn Arg Gln Asn Phe Ile Asn Glu Lys Asn Ile Tyr Arg Val Pro

701 TTGCAACCCG TCAGAATTAA ATCAACGAAA AGAACATTAA CAGAGTGCCT

AACGTTGGC AGTCTTAAA TAGTTGCTTT TCTTGTAAT GTCTCACGGA

+1 Leu Met Glu His Asp Asn Ile Ala Arg Phe Ile Val Gly Asp Glu Arg Val

751 TTGATGGAAC ATGACAACAT TGCCCGCTTT ATAGTTGGAG ATGAGAGAGT

AACTACCTG TACTGTTGTA ACGGCGAAA TATCAACCTC TACTCTCTCA

Figure 5-2

7/9

+1 Val Thr Ala Asp Gly Arg Met Glu Tyr Leu Leu Val Met Glu Tyr Tyr Pro Asn

801 CACTGCAGAT GGACGCATGG AATATTGCT TGTGATGGAG TACTATCCA
GTGACGCTCA CCTCGTACC TTATAAACGA ACACTACCTC ATGATAGGGT

+1 Asn Gly Ser Leu Qs Lys Tyr Leu Ser Leu His Thr Ser Asp Trp Val Ser

851 ATGGATCTTT ATGCAAGTAT TTAAGTCTCC ACACAAGTGA CTGGGTAAGC
TACCTAGAAA TACGTTCAT AATTCAAGAGG TGTGTTCACT GACCCATTG

+1 Ser Qs Arg Leu Ala His Ser Val Thr Arg Gly Leu Ala Tyr Leu His Thr

901 TCTTGCCGTC TTGCTCATTC TGTTACTAGA GGACTGGCTT ATCTTCACAC
AGAACGGCAG AACGAGTAAG ACAATGATCT CCTGACCGAA TAGAAGTGTG

+1 Thr Glu Leu Pro Arg Gly Asp His Tyr Lys Pro Ala Ile Ser His Arg Asp Leu

951 AGAATTACCA CGAGGAGATC ATTATAAACCG TGCAATTCC CATCGAGATT
TCTTAATGGT GCTCCTCTAG TAATATTGG ACGTTAAAGG GTAGCTCTAA

+1 Leu Asn Ser Arg Asn Val Leu Val Lys Asn Asp Gly Thr Qs Val Ile Ser

1001 TAAACAGCAG AAATGTCCTA GTGAAAAATG ATGGAACCTG TGTTATTAGT
ATTGTCGTC TTTACAGGAT CACTTTTAC TACCTGGAC ACAATAATCA

+1 Asp Phe Gly Leu Ser Met Arg Leu Thr Gly Asn Arg Leu Val Arg Pro Gly

1051 GACTTTGGAC TGTCCATGAG GCTGACTGGA AATAGACTGG TGCGCCCAGG
CTGAAACCTG ACAGGTACTC CGACTGACCT TTATCTGACC ACGCGGGTCC

+1 Gly Glu Glu Asp Asn Ala Ala Ile Ser Glu Val Gly Thr Ile Arg Tyr Met Ala

1101 GGAGGAAGAT AATGCAGCCA TAAGCGAGGT TGGCACTATC AGATATATGG
CCTCCTTCTA TTACGTCGGT ATTGCTCCA ACCGTGATAG TCTATATACC

+1 Ala Pro Glu Val Leu Glu Gly Ala Val Asn Leu Arg Asp Qs Glu Ser Ala

1151 CACCAAGAAGT GCTAGAAGGA GCTGTAAC TGAGGGACTG TGAATCAGCT
GTGGTCTTCA CGATCTTCCT CGACACTTGA ACTCCCTGAC ACTTAGTCGA

+1 Leu Lys Glu Val Asp Met Tyr Ala Leu Gly Leu Ile Tyr Trp Glu Ile Phe

1201 TTGAAACAAG TAGACATGTA TGCTCTGGGA CTAATCTATT GGGAGATATT
AACTTTGTTTACAT ACGAGAACCT GATTAGATAA CCCTCTATAA

+1 Phe Met Arg Qs Thr Asp Leu Phe Pro Gly Glu Ser Val Pro Glu Tyr Glu Met

1251 TATGAGATGT ACAGACCTCT TCCCAGGGGA ATCCGTACCA GAGTACCA
ATACTCTACA TGTCTGGAGA AGGGTCCCCCT TAGGCATGGT CTCATGGTCT

+1 Met Ala Phe Glu Thr Glu Val Gly Asn His Pro Thr Phe Glu Asp Met Glu

1301 TGGCTTTCA GACAGAGGTT GGAAACCATC CCACTTTGA GGATATGCAG
ACCGAAAAGT CTGTCTCCAA CCTTTGGTAG GGTGAAAACCT CCTATACGTC

+1 Val Leu Val Ser Arg Glu Lys Glu Arg Pro Lys Phe Pro Glu Ala Trp Lys

1351 GTTCTCGTGT CTAGGGAAAA ACAGAGACCC AAGTTCCAG AAGCCTGGAA
CAAGAGCACA GATCCCTTT TGTCTCTGGG TTCAAGGGTC TTCGGACCTT

+1 Lys Glu Asn Ser Leu Ala Val Arg Ser Leu Lys Glu Thr Ile Glu Asp Qs Trp

1401 AGAAAATAGC CTGGCAGTGA GGTCACTCAA GGAGACAATC GAAGACTGTT
TCTTTTATCG GACCGTCACT CCAGTGAGTT CCTCTGTTAG CTTCTGACAA

+1 Trp Asp Gin Asp Ala Glu Ala Arg Leu Thr Ala Glu Qs Ala Glu Glu Arg

1451 GGGACCAGGA TGCAGAGGCT CGGCTTACTG CACAGTGTGC TGAGGAAAGG
CCCTGGTCT ACCTGCTCCGA GCCGAATGAC GTGTACACG ACTCCTTTCC

+1 Met Ala Glu Leu Met Met Ile Trp Glu Arg Asn Lys Ser Val Ser Pro Thr

1501 ATGGCTGAAC TTATGATGAT TTGGGAAAGA AACAAATCTG TGAGGCCAAC
TACCGACTTG AATACTACTA AACCCCTTCT TTGTTTAGAC ACTCGGGTTG

+1 Thr Val Asn Pro Met Ser Thr Ala Met Glu Asn Glu Arg Asn Leu Ser His Asn

1551 AGTCAATCCA ATGTCTACTG CTATGCAGAA TGAACGCAAC CTGTCACATA
TCAGTTAGGT TACAGATGAC GATACGTCTT ACTTGCCTTG GACAGTGTAT

Figure 5-3

8/9

+1 Asn Arg Arg Val Pro Lys Ile Gly Pro Tyr Pro Asp Tyr Ser Ser Ser Ser
 1601 ATAGGCGTGT GCCAAAAATT GGTCTTATC CAGATTATTC TTCCCTCCTCA
 +1 TATCCGCACA CGGTTTTAA CCAGGAATAG GTCTAATAAG AAGGAGGAGT
 +1 Tyr Ile Glu Asp Ser Ile His His Thr Asp Ser Ile Val Lys Asn Ile Ser
 1651 TACATTGAAG ACTCTATCCA TCATACTGAC AGCATCGTGA AGAATATTTC
 ATGTAACCTTC TGAGATAGGT AGTATGACTG TCGTAGCACT TCTTATAAAG
 +1 Ser Ser Glu His Ser Met Ser Ser Thr Pro Leu Thr Ile Gly Glu Lys Asn Arg
 1701 CTCTGAGCAT TCTATGTCCA GCACACCTT GACTATAGGG GAAAAAAACC
 GAGACTCGTA AGATACAGGT CGTGTGGAAA CTGATATCCC CTTTTTTTGG
 +1 Arg Asn Ser Ile Asn Tyr Glu Arg Gln Gln Ala Gln Ala Arg Ile Pro Ser
 1751 GAAATTCAAT TAACTATGAA CGACAGCAAG CACAAGCTCG AATCCCCAGC
 CTTTAAGTTA ATTGATACTT GCTGTCGTT GGTGTCGAGC TTAGGGGTCG
 +1 Pro Glu Thr Ser Val Thr Ser Leu Ser Thr Asn Thr Thr Thr Asn Thr
 1801 CCTGAAACAA GTGTCACCAAG CCTCTCCACC AACACAACAA CCACAAACAC
 GGACTTTGTT CACAGTGGTC GGAGAGGTGG TTGTGTTGTT GGTGTTGTC
 +1 Thr Thr Gly Leu Thr Pro Ser Thr Gly Met Thr Thr Ile Ser Glu Met Pro Tyr
 1851 CACAGGACTC ACGCCAAGTA CTGGCATGAC TACTATATCT GAGATGCCAT
 GTGTCCTGAG TGCGGTTCAT GACCGTACTG ATGATATAGA CTCTACGGTA
 +1 Tyr Pro Asp Glu Thr Asn Leu His Thr Thr Asn Val Ala Gln Ser Ile Gly
 1901 ACCCAGATGA AACAAATCTG CATACCACAA ATGTTGCACA GTCAATTGGG
 TGGGTCTACT TTGTTTAGAC GTATGGTGGT TACAACGTGT CAGTTAACCC
 +1 Pro Thr Pro Val Qs Leu Gln Leu Thr Glu Glu Asp Leu Glu Thr Asn Lys
 1951 CCAACCCCTG TCTGCTTACA GCTGACAGAA GAAGACTTGG AAACCAACAA
 GGTTGGGGAC AGACGAATGT CGACTGCTT CTTCTGAACC TTTGGTTGTT
 +1 Lys Leu Asp Pro Lys Glu Val Asp Lys Asn Leu Lys Glu Ser Ser Asp Glu Asn
 2001 GCTAGACCCA AAAGAAGTTG ATAAGAACCT CAAGGAAAGC TCTGATGAGA
 CGATCTGGGT TTTCTTCAAC TATTCTTGGA GTTCCTTTCG AGACTACTCT
 +1 Asn Leu Met Glu His Ser Leu Lys Gln Phe Ser Gly Pro Asp Pro Leu Ser
 2051 ATCTCATGGA GCACTCTCTT AAACAGTTCA GTGGCCAGA CCCACTGAGC
 TAGAGTACCT CGTGAGAGAA TTTGTCAAGT CACCGGGTCT GGGTGAETCG
 +1 Ser Thr Ser Ser Ser Leu Leu Tyr Pro Leu Ile Lys Leu Ala Val Glu Ala
 2101 AGTACTAGTT CTAGCTTGCT TTACCCACTC ATAAAAACTTG CAGTAGAAC
 TCATGATCAA GATCGAACGA AATGGGTGAG TATTTGAAC GTCATCTTCG
 +1 Ala Thr Gly Gln Gln Asp Phe Thr Gln Thr Ala Asn Gly Gln Ala Qs Leu Ile
 2151 AACTGGACAG CAGGACTTCA CACAGACTGC AAATGGCCAA GCATGTTGA
 TTGACCTGTC GTCTGAAAGT GTGTCTGACG TTTACCGGTT CGTACAAACT
 +1 Ile Pro Asp Val Leu Pro Thr Gln Ile Tyr Pro Leu Pro Lys Gln Gln Asn
 2201 TTCCTGATGT TCTGCCTACT CAGATCTATC CTCTCCCCAA GCAGCAGAAC
 AAGGACTACA AGACGGATGA GTCTAGATAG GAGAGGGGTT CGTCGTCTG
 +1 Leu Pro Lys Arg Pro Thr Ser Leu Pro Leu Asn Thr Lys Asn Ser Thr Lys
 2251 CTTCCCAAGA GACCTACTAG TTTGCCCTTG AACACCAAAA ATTCAACAAA
 GAAGGGTTCT CTGGATGATC AAACGGAAAC TTGTGGTTTT TAAGTTGTT
 +1 Lys Glu Pro Arg Leu Lys Phe Gly Ser Lys His Lys Ser Asn Leu Lys Gln Val
 2301 AGAGCCCCGG CTAAAATTG GCAGCAAGCA CAAATCAAAC TTGAAACAAG
 TCTCGGGGCC GATTTAACAC CGTCGTTCTG GTTGTAGTTG AACTTTGTT
 +1 Val Glu Thr Gly Val Ala Lys Met Asn Thr Ile Asn Ala Ala Glu Pro His
 2351 TCGAAACTGG AGTTGCCAAG ATGAATACAA TCAATGCAGC AGAACCTCAT
 AGCTTGACC TCAACGGTTC TACTTATGTT AGTTACGTG TCTTGGAGTA

9/9

Figure 5-4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/21999

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; G01N 33/53
US CL : 435/6, 7.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	LANE et al. THE INTERNATIONAL CONSORTIUM. Heterozygous germline mutations in BMPR2, encoding a TGF-B receptor, cause familial primary pulmonary hypertension. Nature Genetics. September 2000, Vol. 26, pages 81-84, especially page 83.	1-63
A,E	US 6,306,622 B1 (ROSENBAUM et al.) 23 October 2001 (23.10.2001).	1-63
A,E	US 6,291,206 B1 (WOZNEY et al.) 18 September 2001 (18.09.2001).	1-63

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	documents which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
31 October 2001 (31.10.2001)	19 NOV 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	<p>Authorized officer <i>Jayne Bridges</i> Kenneth R. Horlick Telephone No. 703-308-0196</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/21999

Continuation of B. FIELDS SEARCHED Item 3:
USPAT, PGPUB, DERWENT WPI, MEDLINE, BIOSIS
search terms: bone morphogenetic protein receptor, mutation, pulmonary, disease, PPH